Unnamed: 0,title,date,stock,sentiment
255664.0,"Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer",2020-06-10 16:07:00-04:00,CLVS,negative
255665.0,"Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.",2020-06-08 11:41:00-04:00,CLVS,positive
255666.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,CLVS,positive
255667.0,Clovis Oncology Reports New Recommendations For Rubraca Tablets In Updated National Comprehensive Cancer Network Guideliness,2020-05-28 08:10:00-04:00,CLVS,negative
255668.0,CORRECTION: Clovis Oncology Will Not Be Presenting Initial Phase 1b/2 Data For Lucitanib With Opdivo At ASCO This Weekend; Earlier Headline Incorrectly Suggested This Event Would Be Upcoming This Week,2020-05-27 14:16:00-04:00,CLVS,neutral
255669.0,Clovis Oncology Option Alert: Jul 17 $10 Calls at the Ask: 526 @ $0.401 vs 4747 OI; Ref=$6.46,2020-05-27 10:57:00-04:00,CLVS,positive
255670.0,"HC Wainwright & Co. Reiterates Buy on Clovis Oncology, Lowers Price Target to $29",2020-05-22 06:55:00-04:00,CLVS,negative
255671.0,"Clovis Oncology Shares Spike To Session High, Up 1%; Traders Circulate Word Rubraca Added To National Comprehensive Cancer Networks To Prostate Cancer Guidelines",2020-05-21 15:45:00-04:00,CLVS,negative
255672.0,"SVB Leerink Maintains Underperform on Clovis Oncology, Lowers Price Target to $4",2020-05-20 06:45:00-04:00,CLVS,negative
255673.0,61 Biggest Movers From Yesterday,2020-05-20 04:50:00-04:00,CLVS,neutral
255674.0,Why Clovis Oncology's Stock Is Trading Lower Today,2020-05-19 15:09:00-04:00,CLVS,negative
255675.0,44 Stocks Moving In Tuesday's Mid-Day Session,2020-05-19 12:48:00-04:00,CLVS,neutral
255676.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,CLVS,positive
255677.0,28 Stocks Moving in Tuesday's Pre-Market Session,2020-05-19 07:20:00-04:00,CLVS,neutral
255678.0,Clovis Oncology P:rices 11M Share Public Offering of Common Stock @$8.05/Share,2020-05-18 20:20:00-04:00,CLVS,positive
255679.0,6 Stocks Moving In Monday's After-Hours Session,2020-05-18 16:54:00-04:00,CLVS,neutral
255680.0,Clovis Oncology shares are trading lower after the company announced a common stock offering of $85 million shares.,2020-05-18 16:11:00-04:00,CLVS,positive
255681.0,Clovis Oncology AnnouncesA Common Stock Offering Of $85 Million Shares,2020-05-18 16:03:00-04:00,CLVS,positive
255682.0,"HC Wainwright & Co. Maintains Buy on Clovis Oncology, Raises Price Target to $33",2020-05-18 06:59:00-04:00,CLVS,neutral
255683.0,Why Clovis Oncology's Stock Spiked Higher Today,2020-05-15 16:04:00-04:00,CLVS,neutral
255684.0,Clovis Oncology shares are trading higher after the company announced the FDA has approved its Rubraca tablets for the treatment of adult patients with a deleterious BRCA mutation-associated metastatic castration-resistant prostate cancer.,2020-05-15 15:54:00-04:00,CLVS,negative
255685.0,"Clovis Oncology Shares Spike To Session High, Up 8.5%; Traders Circulate FDA Access Data Link For Co.'s Rubraca",2020-05-15 14:31:00-04:00,CLVS,positive
255686.0,"The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO",2020-05-15 07:49:00-04:00,CLVS,negative
255687.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,CLVS,neutral
255688.0,"Shares of several healthcare companies are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.",2020-05-07 11:25:00-04:00,CLVS,positive
255689.0,58 Stocks Moving In Wednesday's Mid-Day Session,2020-05-06 13:19:00-04:00,CLVS,neutral
255690.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,CLVS,positive
255691.0,"Benzinga Pro's Top 5 Stocks To Watch for Wed., May 6, 2020: SNY, GRUB, CLVS, NTDOY, FDS",2020-05-06 08:02:00-04:00,CLVS,positive
255692.0,19 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-05-06 07:36:00-04:00,CLVS,neutral
255693.0,Clovis Oncology shares are trading higher after the company reported better-than-expected Q1 sales results.,2020-05-06 07:24:00-04:00,CLVS,positive
255694.0,"H.C. Wainwright Reiterates Buy on Clovis Oncology, Raises Price Target to $29",2020-05-06 07:24:00-04:00,CLVS,neutral
255695.0,Clovis Oncology shares are trading higher after the company reported better-than-expected Q1 sales results.,2020-05-05 16:32:00-04:00,CLVS,positive
255696.0,"Clovis Oncology Q1 EPS $(1.390) Misses $(1.280) Estimate, Sales $42.564M Beat $41.240M Estimate",2020-05-05 16:19:00-04:00,CLVS,negative
255697.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,CLVS,positive
255698.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates,2020-05-03 09:25:00-04:00,CLVS,neutral
255699.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,CLVS,neutral
255700.0,"Benzinga's Top Upgrades, Downgrades For April 27, 2020",2020-04-27 09:32:00-04:00,CLVS,positive
255701.0,Clovis Oncology shares are trading lower after SVB Leerink downgraded the stock from Market Perform to Underperform and announced a price target of $5 per share.,2020-04-27 09:31:00-04:00,CLVS,positive
255702.0,"SVB Leerink Downgrades Clovis Oncology to Underperform, Announces $5 Price Target",2020-04-27 07:24:00-04:00,CLVS,neutral
255703.0,Clovis Oncology Option Alert: May 8 $12.5 Calls Sweep (5) near the Ask: 300 @ $0.35 vs 69 OI; Earnings 5/5 After Close Ref=$9.47,2020-04-23 10:17:00-04:00,CLVS,positive
255704.0,78 Biggest Movers From Yesterday,2020-04-21 04:32:00-04:00,CLVS,neutral
255705.0,54 Stocks Moving In Monday's Mid-Day Session,2020-04-20 12:43:00-04:00,CLVS,neutral
255706.0,Clovis Oncology Option Alert: May 15 $10 Calls Sweep (3) near the Ask: 453 @ $1.65 vs 4278 OI; Earnings 5/5 Before Open [est] Ref=$9.9,2020-04-20 12:24:00-04:00,CLVS,positive
255707.0,12 Short Squeeze Candidates To Watch,2020-04-17 14:07:00-04:00,CLVS,neutral
255708.0,Clovis Oncology Option Alert: Fri $8 Calls Sweep (10) near the Ask: 2007 @ $0.1 vs 12205 OI; Earnings 5/5 Before Open [est] Ref=$8.06,2020-04-17 12:21:00-04:00,CLVS,positive
255709.0,Clovis Oncology Option Alert: Jul 17 $9 Calls Sweep (10) near the Ask: 325 @ $1.5 vs 3990 OI; Earnings 5/5 Before Open [est] Ref=$7.14,2020-04-13 14:35:00-04:00,CLVS,positive
255710.0,Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca,2020-04-09 10:04:00-04:00,CLVS,neutral
255711.0,"Benzinga's Top Upgrades, Downgrades For April 9, 2020",2020-04-09 10:02:00-04:00,CLVS,positive
255712.0,Cloves Oncology shares are trading lower after Bank Of America downgraded the stock from Neutral to Underperform and announced a price target of $6 per share.,2020-04-09 08:14:00-04:00,CLVS,positive
255713.0,"B of A Securities Downgrades Clovis Oncology to Underperform, Announces $6 Price Target",2020-04-09 07:58:00-04:00,CLVS,positive
255714.0,90 Biggest Movers From Friday,2020-03-30 05:10:00-04:00,CLVS,neutral
255715.0,Clovis Oncology shares are trading higher. Not seeing any company-specific news to justify the price action.,2020-03-27 12:41:00-04:00,CLVS,positive
255716.0,"Shares of several healthcare companies are trading higher following Senate passage of a $2 trillion economic stimulus package, which has lifted stocks across sectors.",2020-03-26 11:49:00-04:00,CLVS,positive
255717.0,110 Biggest Movers From Yesterday,2020-03-17 06:13:00-04:00,CLVS,neutral
255718.0,95 Stocks Moving In Monday's Mid-Day Session,2020-03-16 12:00:00-04:00,CLVS,neutral
255719.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,CLVS,negative
255720.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-16 08:32:00-04:00,CLVS,neutral
255721.0,22 Stocks Moving in Monday's Pre-Market Session,2020-03-16 07:24:00-04:00,CLVS,neutral
255722.0,52 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-03-09 08:04:00-04:00,CLVS,neutral
255723.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2020-03-05 07:51:00-05:00,CLVS,neutral
255724.0,Clovis Oncology Option Alert: Mar 20 $7.5 Puts at the Bid: 5000 @ $0.7 vs 701 OI; Ref=$7.87,2020-03-04 12:37:00-05:00,CLVS,positive
255725.0,Clovis Oncology Announces Availability and Reimbursement for Rubraca Tablets for Women with Relapsed Ovarian Cancer in Spain,2020-03-02 05:18:00-05:00,CLVS,negative
255726.0,Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.,2020-02-27 09:28:00-05:00,CLVS,negative
255727.0,80 Biggest Movers From Yesterday,2020-02-26 05:32:00-05:00,CLVS,neutral
255728.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-02-25 12:24:00-05:00,CLVS,neutral
255729.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,CLVS,negative
255730.0,Clovis Oncology shares are trading lower after the company reported worse-than-expected Q4 EPS results.,2020-02-25 07:44:00-05:00,CLVS,neutral
255731.0,77 Biggest Movers From Yesterday,2020-02-25 04:30:00-05:00,CLVS,neutral
255732.0,14 Stocks Moving In Monday's After-Hours Session,2020-02-24 16:51:00-05:00,CLVS,neutral
255733.0,Clovis Oncology shares are trading lower after the company reported worse-than-expected Q4 EPS results.,2020-02-24 16:17:00-05:00,CLVS,neutral
255734.0,"Clovis Oncology Q4 EPS $(1.81) Misses $(1.71) Estimate, Sales $39.307M Beat $38.97M Estimate",2020-02-24 16:10:00-05:00,CLVS,negative
255735.0,55 Stocks Moving In Monday's Mid-Day Session,2020-02-24 13:10:00-05:00,CLVS,neutral
255736.0,Shares of several healthcare and biotech companies are trading lower amid continued spread of coronavirus including notable upticks in Iran and Italy. NOTE: The virus has raised fear of a global economic slowdown.,2020-02-24 08:37:00-05:00,CLVS,negative
255737.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,CLVS,neutral
255738.0,78 Biggest Movers From Yesterday,2020-02-20 05:16:00-05:00,CLVS,neutral
255739.0,Clovis Oncology Option Alert: Apr 17 $10 Calls at the Ask: 3000 @ $2.3 vs 25074 OI; Earnings 2/24 After Close Ref=$10.17,2020-02-19 12:22:00-05:00,CLVS,positive
255740.0,"Clovis Oncology shares are trading higher after the company's CEO and President acquired 50,000 shares at an average price of $9.71 per share. When an insider acquires shares, the market may perceive it as a sign of confidence in the company's outlook.",2020-02-19 11:59:00-05:00,CLVS,positive
255741.0,Clovis Oncology Option Alert: Apr 17 $15 Calls Sweep (13) near the Ask: 1000 @ $0.451 vs 6949 OI; Earnings 2/24 After Close Ref=$9.0288,2020-02-14 14:27:00-05:00,CLVS,positive
255742.0,Clovis Oncology 13G From State Street Shows 6.68% Stake,2020-02-13 08:29:00-05:00,CLVS,neutral
255743.0,4 Stocks Looking Higher During Earnings Season,2020-02-06 15:34:00-05:00,CLVS,neutral
255744.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,CLVS,positive
255745.0,61 Stocks Moving In Monday's Mid-Day Session,2020-02-03 12:25:00-05:00,CLVS,neutral
255746.0,10 Biotechnology Stocks Moving In Monday's Pre-Market Session,2020-02-03 07:30:00-05:00,CLVS,neutral
255747.0,18 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-02-03 07:30:00-05:00,CLVS,neutral
255748.0,30 Stocks Moving in Monday's Pre-Market Session,2020-02-03 07:30:00-05:00,CLVS,neutral
255749.0,Clovis Oncology shares are trading higher after the company announced Rubraca tablets will now be available and reimbursed in France for women with relapsed ovarian cancer.,2020-02-03 07:13:00-05:00,CLVS,negative
255750.0,Clovis Oncology Announces Availability and Reimbursement for Rubraca Tablets for Women with Relapsed Ovarian Cancer in France,2020-02-03 05:08:00-05:00,CLVS,negative
255751.0,90 Biggest Movers From Yesterday,2020-01-30 04:15:00-05:00,CLVS,neutral
255752.0,62 Stocks Moving In Tuesday's Mid-Day Session,2020-01-29 12:25:00-05:00,CLVS,neutral
255753.0,Clovis Oncology shares are trading higher. Not currently seeing any company-specific news from today.,2020-01-29 11:10:00-05:00,CLVS,positive
255754.0,"B of A Securities Maintains Neutral on Clovis Oncology, Raises Price Target to $10",2020-01-23 13:16:00-05:00,CLVS,positive
255755.0,Clovis Oncology Option Alert: Feb 7 $11 Calls Sweep (9) near the Ask: 778 @ $0.3 vs 74 OI; Earnings 2/24 After Close Ref=$9.435,2020-01-23 11:19:00-05:00,CLVS,positive
255756.0,Clovis Oncology Option Alert: Feb 21 $11 Calls at the Ask: 700 @ $0.451 vs 5747 OI; Earnings 2/24 After Close Ref=$9.32,2020-01-23 11:07:00-05:00,CLVS,positive
255757.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,CLVS,neutral
255758.0,116 Healthcare Stocks Moving In Wednesday's Session,2020-01-22 12:37:00-05:00,CLVS,neutral
255759.0,"Clovis Oncology Option Alert: Jan, 2021 $15 Calls at the Ask: 1991 @ $2.5 vs 2268 OI; Earnings 2/24 After Close Ref=$9.515",2020-01-21 13:18:00-05:00,CLVS,positive
255760.0,75 Biggest Movers From Yesterday,2020-01-16 04:37:00-05:00,CLVS,neutral
255761.0,36 Stocks Moving In Wednesday's Mid-Day Session,2020-01-15 12:07:00-05:00,CLVS,neutral
255762.0,Clovis Oncology Option Alert: Jul 17 $6 Puts Sweep (16) near the Bid: 890 @ $1.1 vs 33 OI; Earnings 2/24 After Close Ref=$10.11,2020-01-15 11:08:00-05:00,CLVS,positive
255763.0,FDA Grants Priority Review Designation For Clovis Oncology's Rubraca Label Expansion,2020-01-15 10:22:00-05:00,CLVS,positive
255764.0,Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Reports Mixed Q4 Results,2020-01-15 10:09:00-05:00,CLVS,neutral
255765.0,Clovis Oncology shares are trading higher after Rubraca was granted FDA priority reviewed for advanced prostate cancer.,2020-01-15 08:36:00-05:00,CLVS,negative
255766.0,34 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-15 08:10:00-05:00,CLVS,neutral
255767.0,Clovis Oncology's Rubraca Granted FDA Priority Review For Advanced Prostate Cancer,2020-01-15 08:02:00-05:00,CLVS,negative
255768.0,54 Biggest Movers From Yesterday,2020-01-09 04:47:00-05:00,CLVS,neutral
255769.0,Clovis Oncology shares are trading higher potentially on a rebound after the stock dropped roughly 11% after the company gave preliminary Q4 and FY19 sales guidance for Rubraca. Not seeing any news to justify the price action.,2020-01-08 13:55:00-05:00,CLVS,positive
255770.0,Clovis Oncology Option Alert: Apr 17 $15 Calls at the Ask: 1000 @ $0.43 vs 5494 OI; Earnings 2/25 Before Open [est] Ref=$8.1549,2020-01-08 10:40:00-05:00,CLVS,positive
255771.0,Clovis Oncology shares are trading lower after the company issued its preliminary Q4 and FY19 sales guidance.,2020-01-07 11:26:00-05:00,CLVS,neutral
255772.0,"Clovis Oncology  Sees Prelim. Q4 Rubraca Sales $38.3M-$39.3M, FY19 Rubraca Sales $142.0-$143.0M",2020-01-07 07:30:00-05:00,CLVS,neutral
255773.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,CLVS,neutral
255774.0,Clovis Oncology Option Alert: Fri $12 Puts at the Bid: 4000 @ $0.801 vs 9670 OI; Ref=$11.05,2019-12-20 13:27:00-05:00,CLVS,positive
255775.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-12-17 12:01:00-05:00,CLVS,neutral
255776.0,19 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-17 07:57:00-05:00,CLVS,neutral
255777.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,CLVS,positive
255778.0,30 Stocks Moving in Tuesday's Pre-Market Session,2019-12-17 07:25:00-05:00,CLVS,neutral
255779.0,Clovis Oncology Files For $250M Mixed Shelf Offering,2019-12-16 17:18:00-05:00,CLVS,neutral
255780.0,Clovis Oncology Option Alert: Apr 17 $4 Calls Sweep (2) near the Bid: 13000 @ $8.5 vs 287 OI; Ref=$12.66,2019-12-16 10:32:00-05:00,CLVS,positive
255781.0,Clovis Oncology Highlights Presentation Of first Clinical Experience With FAP-2286 In Named-Patient Use,2019-12-16 08:44:00-05:00,CLVS,neutral
255782.0,Clovis Oncology Option Alert: Jul 17 $13 Calls Sweep (2) near the Ask: 2500 @ $3.275 vs 233 OI; Ref=$12.82,2019-12-13 14:24:00-05:00,CLVS,positive
255783.0,20 Stocks Moving in Friday's Pre-Market Session,2019-12-13 06:48:00-05:00,CLVS,neutral
255784.0,Clovis Oncology Option Alert: Dec 20 $15 Calls Sweep (2) above Ask!: 1000 @ $0.625 vs 5111 OI; Ref=$13.3,2019-12-12 14:12:00-05:00,CLVS,positive
255785.0,Clovis Oncology Option Alert: Jan 17 $10 Calls Sweep (4) near the Ask: 580 @ $3.101 vs 7786 OI; Ref=$12.57,2019-12-12 12:08:00-05:00,CLVS,positive
255786.0,32 Stocks Moving In Wednesday's Pre-Market Session,2019-12-11 07:48:00-05:00,CLVS,neutral
255787.0,66 Biggest Movers From Yesterday,2019-12-11 04:52:00-05:00,CLVS,neutral
255788.0,Clovis Oncology Option Alert: Dec 20 $12 Puts at the Bid: 4000 @ $1.15 vs 6115 OI; Ref=$12.39,2019-12-10 14:03:00-05:00,CLVS,positive
255789.0,"Clovis Oncology shares are trading higher on continued momentum after Jim Cramer, on CNBC's ""Mad Money,"" said he thinks the company is a good spec.",2019-12-10 10:37:00-05:00,CLVS,positive
255790.0,41 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-10 08:10:00-05:00,CLVS,neutral
255791.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,CLVS,neutral
255792.0,Clovis Oncology Option Alert: Apr 17 $8 Puts at the Bid: 1600 @ $2.25 vs 3998 OI; Ref=$10.3913,2019-12-09 14:36:00-05:00,CLVS,positive
255793.0,"Clovis Oncology shares are trading higher after Jim Cramer, on CNBC's ""Mad Money,"" said he thinks the company is a good spec.",2019-12-09 10:04:00-05:00,CLVS,positive
255794.0,"Cramer Gives His Take On Bank Of America, BlackBerry And More",2019-12-09 07:18:00-05:00,CLVS,neutral
255795.0,74 Biggest Movers From Friday,2019-12-09 05:22:00-05:00,CLVS,neutral
255796.0,55 Stocks Moving In Friday's Mid-Day Session,2019-12-06 12:02:00-05:00,CLVS,neutral
255797.0,"Clovis Oncology shares are trading higher in sympathy with the overall market after the U.S. added 266,000 jobs in November, beating expectations and lowering the unemployment rate to 3.5%.",2019-12-06 10:06:00-05:00,CLVS,negative
255798.0,75 Biggest Movers From Yesterday,2019-12-06 05:36:00-05:00,CLVS,neutral
255799.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-12-05 12:07:00-05:00,CLVS,neutral
255800.0,Clovis Oncology shares are trading lower. Not currently seeing any company-specific news to explain sell off.,2019-12-05 09:42:00-05:00,CLVS,neutral
255801.0,Clovis Oncology shares are trading higher. Strength may be due to a potential rebound after the stock fell roughly 25% yesterday.,2019-12-04 09:09:00-05:00,CLVS,positive
255802.0,12 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-12-04 07:34:00-05:00,CLVS,neutral
255803.0,63 Biggest Movers From Yesterday,2019-12-04 05:15:00-05:00,CLVS,neutral
255804.0,Clovis Oncology Option Alert: Jan 17 $15 Calls Sweep (12) near the Ask: 500 @ $2.45 vs 4318 OI; Ref=$13.85,2019-12-03 14:40:00-05:00,CLVS,positive
255805.0,Clovis Oncology Option Alert: Jan 17 $25 Calls Sweep (23) near the Ask: 585 @ $0.794 vs 2858 OI; Ref=$14.13,2019-12-03 14:37:00-05:00,CLVS,positive
255806.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-12-03 12:20:00-05:00,CLVS,neutral
255807.0,Clovis Oncology shares are trading lower following recent upward momentum. Weakness potentially related to investor doubts over recent M&A speculation.,2019-12-03 11:08:00-05:00,CLVS,negative
255808.0,19 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-12-03 07:46:00-05:00,CLVS,neutral
255809.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,CLVS,neutral
255810.0,Clovis Oncology shares are trading higher on seemingly no company-specific news. NOTE: Since November 5th the stock has rallied roughly 350%.,2019-12-02 11:54:00-05:00,CLVS,neutral
255811.0,10 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-02 07:24:00-05:00,CLVS,neutral
255812.0,52 Biggest Movers From Friday,2019-12-02 04:44:00-05:00,CLVS,neutral
255813.0,35 Stocks Moving In Friday's Mid-Day Session,2019-11-29 11:40:00-05:00,CLVS,neutral
255814.0,Clovis Oncology shares are trading higher. Not seeing any news to justify the price action.,2019-11-29 10:32:00-05:00,CLVS,positive
255815.0,52 Biggest Movers From Wednesday,2019-11-29 05:26:00-05:00,CLVS,neutral
255816.0,Clovis Oncology Option Alert: Jan 17 $15 Calls at the Ask: 704 @ $1.591 vs 1155 OI; Ref=$12.39,2019-11-27 14:25:00-05:00,CLVS,positive
255817.0,Clovis Oncology shares are trading higher. Not seeing any news to justify the price action.,2019-11-27 10:25:00-05:00,CLVS,positive
255818.0,Clovis Oncology shares are trading on above-average volume. NOTE: The stock has rallied approximately 44% over the past 5 trading sessions.,2019-11-26 13:46:00-05:00,CLVS,positive
255819.0,Clovis Oncology Option Alert: Apr 17 $7 Puts Sweep (3) near the Bid: 654 @ $1.601 vs 12408 OI; Ref=$11.42,2019-11-26 13:18:00-05:00,CLVS,positive
255820.0,14 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-11-26 07:58:00-05:00,CLVS,neutral
255821.0,45 Biggest Movers From Yesterday,2019-11-26 07:05:00-05:00,CLVS,neutral
255822.0,Clovis Oncology shares are trading higher on above-average volume. Not seeing any news to justify the price action.,2019-11-25 11:13:00-05:00,CLVS,positive
255823.0,Clovis Oncology Option Alert: Apr 17 $6 Puts Sweep (5) near the Bid: 500 @ $1.051 vs 3440 OI; Ref=$9.3348,2019-11-25 09:46:00-05:00,CLVS,positive
255824.0,36 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-25 08:40:00-05:00,CLVS,neutral
255825.0,3 Momentum Stocks To Watch Post-Earnings,2019-11-22 12:56:00-05:00,CLVS,neutral
255826.0,Clovis Oncology Option Alert: Dec 20 $6 Calls Sweep (3) near the Ask: 971 @ $2.484 vs 4367 OI; Ref=$8.4,2019-11-22 11:58:00-05:00,CLVS,positive
255827.0,Clovis Oncology shares are trading higher. Not seeing any news to justify the price action.,2019-11-22 10:27:00-05:00,CLVS,positive
255828.0,66 Biggest Movers From Yesterday,2019-11-22 04:50:00-05:00,CLVS,neutral
255829.0,Clovis Oncology shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock has rallied approximately 116% over the past month.,2019-11-21 11:43:00-05:00,CLVS,positive
255830.0,22 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-21 07:47:00-05:00,CLVS,neutral
255831.0,63 Biggest Movers From Yesterday,2019-11-21 04:49:00-05:00,CLVS,neutral
255832.0,Clovis Oncology shares are trading lower in sympathy with weakness in the overall market after it was reported phase one of the US-China trade deal may not happen this year.,2019-11-20 14:37:00-05:00,CLVS,negative
255833.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-11-20 12:09:00-05:00,CLVS,neutral
255834.0,33 Stocks Moving in Wednesday's Pre-Market Session,2019-11-20 07:16:00-05:00,CLVS,neutral
255835.0,77 Biggest Movers From Yesterday,2019-11-20 04:57:00-05:00,CLVS,neutral
255836.0,Clovis Oncology Option Alert: Dec 20 $10 Calls at the Ask: 974 @ $0.41 vs 904 OI; Ref=$7.58,2019-11-19 14:29:00-05:00,CLVS,positive
255837.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-11-19 12:45:00-05:00,CLVS,neutral
255838.0,Clovis Oncology shares are trading higher. Not seeing any news to justify the price action.,2019-11-19 10:15:00-05:00,CLVS,positive
255839.0,"Benzinga's Top Upgrades, Downgrades For November 19, 2019",2019-11-19 09:57:00-05:00,CLVS,positive
255840.0,8 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-11-19 07:39:00-05:00,CLVS,neutral
255841.0,28 Stocks Moving in Tuesday's Pre-Market Session,2019-11-19 07:14:00-05:00,CLVS,neutral
255842.0,"Evercore ISI Group Downgrades Clovis Oncology to In-Line, Announces $8 Price Target",2019-11-19 06:58:00-05:00,CLVS,neutral
255843.0,72 Biggest Movers From Yesterday,2019-11-19 04:39:00-05:00,CLVS,neutral
255844.0,19 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-14 07:35:00-05:00,CLVS,neutral
255845.0,81 Biggest Movers From Yesterday,2019-11-14 05:20:00-05:00,CLVS,neutral
255846.0,54 Stocks Moving In Wednesday's Mid-Day Session,2019-11-13 12:08:00-05:00,CLVS,neutral
255847.0,Clovis Oncology shares are trading higher after the company announced that the Italian Medicines Agency has approved the company's Rucaparib for reimbursement in Italy.,2019-11-13 10:00:00-05:00,CLVS,positive
255848.0,80 Biggest Movers From Friday,2019-11-11 04:51:00-05:00,CLVS,neutral
255849.0,Mid-Afternoon Market Update: Sientra Rises Following Q3 Results; AnaptysBio Shares Slide,2019-11-08 14:22:00-05:00,CLVS,positive
255850.0,65 Stocks Moving In Friday's Mid-Day Session,2019-11-08 13:15:00-05:00,CLVS,neutral
255851.0,Mid-Day Market Update: Modine Manufacturing Drops After Q2 Results; Ubiquiti Shares Climb,2019-11-08 12:36:00-05:00,CLVS,positive
255852.0,Clovis Oncology shares are trading higher following Q3 results. The company reported better-than-expected EPS and sales and a 42% year-over-year drop in cash burn.,2019-11-08 11:02:00-05:00,CLVS,neutral
255853.0,94 Biggest Movers From Yesterday,2019-11-08 06:01:00-05:00,CLVS,neutral
255854.0,75 Stocks Moving In Thursday's Mid-Day Session,2019-11-07 12:19:00-05:00,CLVS,neutral
255855.0,Clovis Oncology shares are trading higher following Q3 results. The company reported better-than-expected EPS and sales and a 42% year-over-year drop in cash burn.,2019-11-07 08:59:00-05:00,CLVS,neutral
255856.0,"Clovis Oncology Earlier Reported Q3 EPS $(1.85) Beats $(1.89) Estimate, Sales $37.603M Beat $35.84M Estimate",2019-11-07 08:57:00-05:00,CLVS,neutral
255857.0,23 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-11-07 08:04:00-05:00,CLVS,neutral
255858.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,CLVS,negative
255859.0,24 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-11-04 08:13:00-05:00,CLVS,neutral
255860.0,"The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight",2019-11-03 10:51:00-05:00,CLVS,neutral
255861.0,Clovis Oncology shares are trading higher on seemingly no company-specific news.,2019-11-01 13:52:00-04:00,CLVS,neutral
255862.0,46 Biggest Movers From Yesterday,2019-10-29 05:39:00-04:00,CLVS,neutral
255863.0,"Clovis Oncology Option Alert: Jan, 2021 $13 Calls at the Bid: 20000 @ $0.5 vs 20487 OI; Earnings 11/7 Before Open Ref=$3.73",2019-10-28 12:17:00-04:00,CLVS,positive
255864.0,"Clovis Oncology Shares Resume Trade, Continue Higher, Up 26.7% For Session",2019-10-28 11:59:00-04:00,CLVS,positive
255865.0,Clovis Oncology shares are trading higher on seemingly no company-specific news. The company has experienced heavy spike in volume.,2019-10-28 11:56:00-04:00,CLVS,neutral
255866.0,"Clovis Oncology Shares Halted On Circuit Breaker, Up 23%, On Very Heavy Spike In Volume",2019-10-28 11:54:00-04:00,CLVS,positive
255867.0,Clovis Oncology Option Alert: Nov 15 $4 Calls Sweep (30) near the Ask: 658 @ $0.401 vs 3054 OI; Earnings 11/7 Before Open Ref=$3.51,2019-10-28 11:53:00-04:00,CLVS,positive
255868.0,Stocks That Hit 52-Week Lows On Monday,2019-10-28 11:12:00-04:00,CLVS,negative
255869.0,Biotech Stock On The Radar: Immunomedics' Long Wait For Redemption,2019-10-23 16:27:00-04:00,CLVS,neutral
255870.0,33 Stocks Moving In Monday's Mid-Day Session,2019-10-21 12:32:00-04:00,CLVS,neutral
255871.0,26 Stocks Moving in Monday's Pre-Market Session,2019-10-21 07:41:00-04:00,CLVS,neutral
255872.0,32 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-18 08:34:00-04:00,CLVS,neutral
255873.0,48 Biggest Movers From Yesterday,2019-10-18 06:55:00-04:00,CLVS,neutral
255874.0,Clovis Oncology shares are trading higher on seemingly no company-specific news.,2019-10-17 12:41:00-04:00,CLVS,neutral
255875.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., October 16, 2019",2019-10-16 12:47:00-04:00,CLVS,positive
255876.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-15 11:05:00-04:00,CLVS,negative
255877.0,"The Daily Biotech Pulse: Reata Leaps On Positive Readout, Takeda Divests, FDA Nod For Akorn, J&J Earnings",2019-10-15 07:50:00-04:00,CLVS,positive
255878.0,Clovis Oncology Reports Rubraca Now Available In England For Women With Relapse Ovarian Cancer,2019-10-11 09:20:00-04:00,CLVS,negative
255879.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,CLVS,positive
255880.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,CLVS,neutral
255881.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Wed., October 09, 2019",2019-10-09 14:25:00-04:00,CLVS,positive
255882.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-09 12:55:00-04:00,CLVS,negative
255883.0,"The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug",2019-10-09 07:58:00-04:00,CLVS,negative
255884.0,42 Biggest Movers From Yesterday,2019-10-09 05:05:00-04:00,CLVS,neutral
255885.0,Clovis Oncology shares are trading lower after Goldman Sachs maintained its Sell rating on the stock and lowered the price target from $13 to $3 per share.,2019-10-08 14:23:00-04:00,CLVS,positive
255886.0,30 Stocks Moving In Tuesday's Mid-Day Session,2019-10-08 12:30:00-04:00,CLVS,neutral
255887.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-08 12:02:00-04:00,CLVS,negative
255888.0,"Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks",2019-10-08 11:08:00-04:00,CLVS,positive
255889.0,"UPDATE: Goldman On Clovis Oncology Also Notes 'Given the diminished topline outlook and continuing investment in rucaparib label expansion, we see the high cash burn and convertible debt burden continuing to be overhangs on the stock'",2019-10-08 10:59:00-04:00,CLVS,negative
255890.0,"UPDATE: Goldman Reiterates Sell On Clovis Oncology, Lowers Target To $3 As Firm Sees 'risk to longer term consensus estimates that embed meaningful growth driven from Rubraca use in prostate cancer and frontline/combo use with PD-1s'",2019-10-08 10:59:00-04:00,CLVS,negative
255891.0,"Goldman Sachs Maintains Sell on Clovis Oncology, Lowers Price Target to $3",2019-10-08 09:16:00-04:00,CLVS,negative
255892.0,"The Daily Biotech Pulse: D-Day For Clinuvel, Qiagen Warns Of Q3 Shortfall, Prevail Announces Gene Therapy Collaboration",2019-10-08 07:11:00-04:00,CLVS,negative
255893.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Mon., October 07, 2019",2019-10-07 12:50:00-04:00,CLVS,positive
255894.0,Stocks That Hit 52-Week Lows Of Monday,2019-10-07 11:09:00-04:00,CLVS,negative
255895.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,CLVS,negative
255896.0,"The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines",2019-10-01 08:10:00-04:00,CLVS,negative
255897.0,Stocks That Hit 52-Week Lows On Monday,2019-09-30 11:20:00-04:00,CLVS,negative
255898.0,Clovis Oncology Early Sunday Highlighted RubracaÂ® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019,2019-09-30 10:40:00-04:00,CLVS,negative
255899.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,CLVS,positive
255900.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,CLVS,neutral
255901.0,"The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug",2019-09-25 07:13:00-04:00,CLVS,positive
255902.0,58 Biggest Movers From Yesterday,2019-09-25 04:54:00-04:00,CLVS,neutral
255903.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,CLVS,negative
255904.0,40 Stocks Moving In Tuesday's Mid-Day Session,2019-09-24 12:54:00-04:00,CLVS,neutral
255905.0,"Benzinga's Top Upgrades, Downgrades For September 24, 2019",2019-09-24 09:46:00-04:00,CLVS,positive
255906.0,Clovis Oncology shares are trading lower after SVB Leerink downgraded the stock from Outperform to Market Perform.,2019-09-24 09:43:00-04:00,CLVS,neutral
255907.0,"The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger",2019-09-24 08:12:00-04:00,CLVS,positive
255908.0,14 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-24 08:07:00-04:00,CLVS,neutral
255909.0,SVB Leerink Downgrades Clovis Oncology to Market Perform,2019-09-24 06:41:00-04:00,CLVS,neutral
255910.0,Stocks That Hit 52-Week Lows On Monday,2019-09-23 13:35:00-04:00,CLVS,negative
255911.0,Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals for $12M Upfront Plus Potential Milestones and Royalties,2019-09-23 04:04:00-04:00,CLVS,neutral
255912.0,"The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering",2019-09-20 07:46:00-04:00,CLVS,positive
255913.0,Clovis Oncology shares are trading lower. Shares fell more than 50% to below $10 at the beginning of August following weak Q2 results and a senior notes offering. The stock has traded largely between $5 and $6 since then.,2019-09-17 13:14:00-04:00,CLVS,negative
255914.0,Clovis Oncology shares are trading lower after the company announced that three posters highlighting studies from the Rubraca clinical development program will be presented at the ESMO Congress 2019.,2019-09-12 12:20:00-04:00,CLVS,neutral
255915.0,Clovis Oncology to Highlight Expanded Data from Rubraca TRITON and ARIEL Clinical Programs in Prostate and Ovarian Cancers at the ESMO Congress 2019,2019-09-12 04:01:00-04:00,CLVS,positive
255916.0,Clovis Oncology Option Alert: Jan 17 $6 Puts Sweep (2) below Bid!: 2000 @ $1.326 vs 277 OI; Earnings 10/29 After Close [est] Ref=$5.8245,2019-09-11 10:41:00-04:00,CLVS,positive
255917.0,80 Biggest Movers From Yesterday,2019-09-11 05:11:00-04:00,CLVS,neutral
255918.0,22 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-08-20 08:32:00-04:00,CLVS,neutral
255919.0,"The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine",2019-08-20 07:33:00-04:00,CLVS,negative
255920.0,Clovis Oncology 13G Shows Whitebox Advisors Holds 7% Stake In Co.,2019-08-19 16:54:00-04:00,CLVS,neutral
255921.0,Shares of several healthcare companies are trading higher on renewed hopes of a resolution to trade tensions between the US and China.,2019-08-19 13:13:00-04:00,CLVS,positive
255922.0,60 Biggest Movers From Friday,2019-08-19 05:00:00-04:00,CLVS,neutral
255923.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal",2019-08-16 13:37:00-04:00,CLVS,negative
255924.0,41 Stocks Moving In Friday's Mid-Day Session,2019-08-16 12:27:00-04:00,CLVS,neutral
255925.0,AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis,2019-08-13 10:58:00-04:00,CLVS,positive
255926.0,"Benzinga's Top Upgrades, Downgrades For August 13, 2019",2019-08-13 09:46:00-04:00,CLVS,positive
255927.0,10 Biggest Price Target Changes For Tuesday,2019-08-13 09:14:00-04:00,CLVS,neutral
255928.0,16 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-08-13 08:36:00-04:00,CLVS,neutral
255929.0,31 Stocks Moving In Tuesday's Pre-Market Session,2019-08-13 08:21:00-04:00,CLVS,neutral
255930.0,"Bank of America Downgrades Clovis Oncology to Neutral, Lowers Price Target to $7",2019-08-13 07:56:00-04:00,CLVS,negative
255931.0,Clovis Oncology shares are trading lower after the company announced the pricing of $250 million of convertible senior notes.,2019-08-09 12:33:00-04:00,CLVS,neutral
255932.0,31 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-09 09:00:00-04:00,CLVS,neutral
255933.0,52 Stocks Moving In Friday's Pre-Market Session,2019-08-09 08:30:00-04:00,CLVS,neutral
255934.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,CLVS,negative
255935.0,110 Biggest Movers From Yesterday,2019-08-09 05:15:00-04:00,CLVS,neutral
255936.0,50 Healthcare Stocks Moving In Thursday's After-Market Session,2019-08-08 21:56:00-04:00,CLVS,neutral
255937.0,90 Stocks Moving In Thursday's Mid-Day Session,2019-08-08 12:50:00-04:00,CLVS,neutral
255938.0,Clovis Oncology shares are trading lower after the company launched a $225 million convertible debt offering.,2019-08-08 11:45:00-04:00,CLVS,negative
255939.0,"The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering",2019-08-08 07:11:00-04:00,CLVS,neutral
255940.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,CLVS,neutral
255941.0,Stocks That Set New 52-Week Lows Friday Morning,2019-08-02 10:46:00-04:00,CLVS,negative
255942.0,"Benzinga's Top Upgrades, Downgrades For August 2, 2019",2019-08-02 09:40:00-04:00,CLVS,positive
255943.0,Guggenheim Downgrades Clovis Oncology to Neutral,2019-08-02 07:41:00-04:00,CLVS,neutral
255944.0,100 Biggest Movers From Yesterday,2019-08-02 05:53:00-04:00,CLVS,neutral
255945.0,72 Stocks Moving In Thursday's Mid-Day Session,2019-08-01 12:16:00-04:00,CLVS,neutral
255946.0,Stocks that Reached Yearly Lows Thursday Morning,2019-08-01 11:09:00-04:00,CLVS,negative
255947.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-01 09:38:00-04:00,CLVS,neutral
255948.0,Clovis Oncology shares are trading lower after the company reported worse-than-expected Q2 EPS and sales results.,2019-08-01 09:05:00-04:00,CLVS,neutral
255949.0,"Clovis Oncology Q2 EPS $(2.27) Misses $(1.71) Estimate, Sales $32.98M Miss $34.92M Estimate",2019-08-01 08:46:00-04:00,CLVS,negative
255950.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,CLVS,negative
255951.0,42 Stocks Moving In Wednesday's Pre-Market Session,2019-07-31 08:17:00-04:00,CLVS,neutral
255952.0,Clovis Oncology Option Alert: Aug 16 $13 Calls Sweep (2) above Ask!: 1000 @ $0.325 vs 871 OI; Earnings 8/1 Before Open Ref=$10.64,2019-07-29 12:56:00-04:00,CLVS,positive
255953.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,CLVS,negative
255954.0,Stocks That Managed to Breach 52-Week Lows Friday,2019-07-26 15:45:00-04:00,CLVS,negative
255955.0,Clovis Oncology shares are trading lower after its S-3 showed registration for about 1.48 million shares common stock offering by the selling of shareholders.,2019-07-02 13:40:00-04:00,CLVS,positive
255956.0,Clovis Oncology S-3 Shows Registration For ~1.48M Share Common Stock Offering Via Selling Shareholders,2019-07-02 09:18:00-04:00,CLVS,positive
255957.0,Clovis Oncology Option Alert: Jul 19 $14 Calls Sweep (43) near the Ask: 964 @ $0.551 vs 507 OI; Earnings 7/31 After Close [est] Ref=$12.6999,2019-06-26 15:48:00-04:00,CLVS,positive
255958.0,60 Biggest Movers From Yesterday,2019-06-25 05:12:00-04:00,CLVS,neutral
255959.0,Shares of several companies in the biotech space are trading higher after Pfizer announced it will acquire Array BioPharma.,2019-06-17 10:10:00-04:00,CLVS,positive
255960.0,"Clovis Oncology Announces Agreement to Settle Lawsuit Filed By Antipodean Against Co, Certain Officers and Directors; Clovis to Pay to Antipodean $4M in Cash, $21M in Shares of Clovis Stock",2019-06-17 06:10:00-04:00,CLVS,positive
255961.0,Clovis Oncology Discloses Amended And Restated Certificate Of Incorporation To Increase Number Of Shares Of Common Stock Authorized For Issuance From 100M To 200M,2019-06-11 16:40:00-04:00,CLVS,positive
255962.0,"The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix",2019-06-07 07:24:00-04:00,CLVS,positive
255963.0,"Clovis Oncology Option Alert: Jan, 2021 $20 Calls Sweep (9) near the Ask: 500 @ $4.8 vs 22898 OI; Earnings 7/31 After Close [est] Ref=$15.21",2019-06-03 10:54:00-04:00,CLVS,positive
255964.0,Clovis Oncology Announces Expanded Rubraca Data from ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at #ASCO19,2019-06-01 07:34:00-04:00,CLVS,neutral
255965.0,"Clovis Oncology Option Alert: Jan, 2021 $20 Calls at the Ask: 800 @ $4.581 vs 20748 OI; Ref=$15.1",2019-05-29 11:18:00-04:00,CLVS,positive
255966.0,"Benzinga's Top Upgrades, Downgrades For May 29, 2019",2019-05-29 09:26:00-04:00,CLVS,positive
255967.0,"Goldman Sachs Downgrades Clovis Oncology to Sell, Lowers Price Target to $15 Price Target",2019-05-29 08:09:00-04:00,CLVS,negative
255968.0,Clovis Oncology Option Alert: Jan 17 $20 Calls at the Ask: 3500 @ $3.0 vs 187 OI; Ref=$16.8002,2019-05-24 13:57:00-04:00,CLVS,negative
255969.0,"Clovis Oncology Option Alert: Jan, 2021 $20 Calls at the Ask: 20000 @ $5.901 vs 207 OI; Ref=$16.75",2019-05-24 11:17:00-04:00,CLVS,positive
255970.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,CLVS,negative
255971.0,Clovis Oncology Highlights 4 Abstracts At ASCO,2019-05-16 08:09:00-04:00,CLVS,neutral
255972.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,CLVS,neutral
255973.0,"Clovis Oncology Q1 EPS $(1.63) Beats $(1.74) Estimate, Sales $33.118M Beat $32.24M Estimate",2019-05-07 08:14:00-04:00,CLVS,neutral
255974.0,Clovis Oncology Enters Into Non-Dilutive Clinical Trial Financing With TPG Sixth Street Partners For Up To $175M,2019-05-02 08:18:00-04:00,CLVS,neutral
255975.0,44 Biggest Movers From Yesterday,2019-04-16 05:44:00-04:00,CLVS,neutral
255976.0,34 Stocks Moving In Monday's Mid-Day Session,2019-04-15 12:16:00-04:00,CLVS,neutral
255977.0,30 Stocks Moving In Monday's Pre-Market Session,2019-04-15 09:01:00-04:00,CLVS,neutral
255978.0,Clovis Oncology shares are trading lower after the company announced it would stop its Phase 2 ATLAS study of Rubraca.,2019-04-15 08:47:00-04:00,CLVS,negative
255979.0,"UPDATE: Clovis Says Data 'suggest that Rubraca provides disease control with no new safety signals in 19 evaluable platinum-sensitive patients with germline BRCA1, germline or somatic BRCA2, or germline PALB2 mutations'",2019-04-02 08:34:00-04:00,CLVS,positive
255980.0,"Clovis Oncology Reports Interim Results From Rubraca Phase 2 Study In Advanced Pancreatic Cancer, Nonclinical Data In Multiple Solid Tumor Types For Rucaparib, Lucitanib Presented At AACR Meeting",2019-04-02 08:34:00-04:00,CLVS,negative
255981.0,"The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial",2019-04-02 07:30:00-04:00,CLVS,neutral
255982.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,CLVS,neutral
255983.0,Clovis Oncology To Present At 2019 AACR Annual Meeting,2019-03-19 08:05:00-04:00,CLVS,neutral
255984.0,Clovis Oncology Option Alert: Apr 18 $30 Calls Sweep (2) near the Ask: 1750 @ $2.175 vs 2555 OI; Earnings 5/7 After Close [est] Ref=$27.2,2019-03-08 13:47:00-05:00,CLVS,positive
255985.0,Clovis Oncology Announces Availability of Rubraca Tablets for Women with Relapsed Ovarian Cancer in Germany,2019-03-04 03:58:00-05:00,CLVS,negative
255986.0,84 Biggest Movers From Yesterday,2019-02-28 05:10:00-05:00,CLVS,neutral
255987.0,72 Stocks Moving In Wednesday's Mid-Day Session,2019-02-27 12:20:00-05:00,CLVS,neutral
255988.0,"Clovis Oncology Q4 EPS $(1.88) Misses $(1.73) Estimate, Sales $30.351M Beat $26.91M Estimate",2019-02-26 08:18:00-05:00,CLVS,negative
255989.0,"The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote",2019-02-26 07:56:00-05:00,CLVS,positive
255990.0,Clovis Oncology Option Alert: Mar 15 $27 Calls Sweep (2) near the Ask: 900 @ $1.925 vs 2664 OI; Earnings 2/26 Before Open Ref=$25.78,2019-02-25 10:22:00-05:00,CLVS,positive
255991.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs",2019-02-22 13:55:00-05:00,CLVS,neutral
255992.0,Clovis Oncology Option Alert: Mar 15 $27 Calls at the Ask: 1300 @ $1.65 vs 737 OI; Earnings 2/26 Before Open Ref=$24.62,2019-02-19 13:40:00-05:00,CLVS,positive
255993.0,Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies,2019-02-19 07:01:00-05:00,CLVS,negative
255994.0,"Centers For Medicaid, Medicare Has Proposed Coverage With Evidence Development For CAR-T Therapy, Decision Would Provide Nationwide Consistency In CMS Coverage",2019-02-15 09:01:00-05:00,CLVS,neutral
255995.0,"Benzinga's Top Upgrades, Downgrades For February 13, 2019",2019-02-13 09:11:00-05:00,CLVS,positive
255996.0,"H.C. Wainwright Initiates Coverage On Clovis Oncology with Buy Rating, Announces $40 Price Target",2019-02-13 07:29:00-05:00,CLVS,neutral
255997.0,Clovis Oncology Option Alert: Fri $25 Calls at the Ask: 500 @ $0.85 vs 1566 OI; Earnings 2/25 After Close [est] Ref=$24.62,2019-02-11 14:29:00-05:00,CLVS,positive
255998.0,Clovis Oncology Option Alert: Apr 18 $30 Calls at the Bid: 1000 @ $2.65 vs 3383 OI; Earnings 2/25 After Close [est] Ref=$26.01,2019-02-06 13:59:00-05:00,CLVS,positive
255999.0,Clovis Oncology Reports Rucaparib Is Now Available To Patients Regardless Of Their BRCA Mutation Status,2019-01-24 12:30:00-05:00,CLVS,neutral
256000.0,"'Clovis Oncology receives European Commission approval of Rubraca as a maintenance treatment for women with relapsed ovarian cancer.' -TradeHawk Tweets, Citing Screenshot Of Document",2019-01-23 14:01:00-05:00,CLVS,positive
256001.0,Clovis Oncology Option Alert: Fri $22.5 Calls Sweep (7) near the Ask: 888 @ $1.598 vs 6370 OI; Earnings 2/25 After Close [est] Ref=$23.91,2019-01-18 15:55:00-05:00,CLVS,positive
256002.0,22 Stocks Moving In Wednesday's Pre-Market Session,2019-01-09 08:02:00-05:00,CLVS,neutral
256003.0,65 Biggest Movers From Yesterday,2019-01-08 05:16:00-05:00,CLVS,neutral
256004.0,42 Stocks Moving In Monday's Mid-Day Session,2019-01-07 13:49:00-05:00,CLVS,neutral
256005.0,Shares of several cancer therapeutics companies are trading higher after Loxo Oncology received an acquisition offer from Eli Lilly.,2019-01-07 10:57:00-05:00,CLVS,negative
256006.0,Clovis Oncology Sees Rubraca Q4 Sales $30.3M to $30.8M,2019-01-07 08:00:00-05:00,CLVS,neutral
256007.0,Activist To Push Clovis To Explore A Sale,2018-12-17 13:12:00-05:00,CLVS,neutral
256008.0,26 Stocks Moving In Friday's Mid-Day Session,2018-12-14 12:21:00-05:00,CLVS,neutral
256009.0,Clovis Oncology Option Alert: Dec 21 $22 Calls Sweep (2) near the Ask: 500 @ $1.351 vs 477 OI; Ref=$21.28,2018-12-13 14:18:00-05:00,CLVS,positive
256010.0,Shares of Clovis Oncology trading higher after the CHMP granted a positive opinion for a new indication of the company's Rubraca tablets for ovarian cancer.,2018-12-13 12:50:00-05:00,CLVS,positive
256011.0,CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer,2018-12-13 12:46:00-05:00,CLVS,neutral
256012.0,"Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate",2018-12-11 12:42:00-05:00,CLVS,positive
256013.0,"UPDATE: Gabelli On Clovis Says Continues 'to believe Bristol, Sanofi and Roche to be the most interested buyers'",2018-12-11 10:39:00-05:00,CLVS,positive
256014.0,"Clovis Oncology Shares Up 3.8%; Gabelli Issued Earlier Note Highlighting Stock As The Top Biotech Pick For 2019 Given Tesaro Acquisition, 'CLVS will become the only standalone PARP, which we believe makes it the most likely takeout target in 2019'",2018-12-11 10:36:00-05:00,CLVS,positive
256015.0,50 Biggest Movers From Tuesday,2018-12-06 05:17:00-05:00,CLVS,neutral
256016.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-12-04 13:14:00-05:00,CLVS,neutral
256017.0,Clovis Oncology shares are trading higher after the European Patent Office upheld patent claims to protect its Rubraca Crystalline.,2018-12-04 08:04:00-05:00,CLVS,positive
256018.0,25 Stocks Moving In Tuesday's Pre-Market Session,2018-12-04 08:03:00-05:00,CLVS,neutral
256019.0,Clovis Oncology Reports European Patent Office Upheld Patent Claims Directed To Rubraca Crystalline,2018-12-04 07:38:00-05:00,CLVS,neutral
256020.0,56 Biggest Movers From Yesterday,2018-12-04 05:02:00-05:00,CLVS,neutral
256021.0,46 Stocks Moving In Monday's Mid-Day Session,2018-12-03 12:37:00-05:00,CLVS,neutral
256022.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Dec. 3, 2018",2018-12-03 12:17:00-05:00,CLVS,positive
256023.0,Clovis Oncology shares are trading high in sympathy with the 60% acquisition premium paid for TESARO.,2018-12-03 08:26:00-05:00,CLVS,positive
256024.0,28 Stocks Moving In Monday's Pre-Market Session,2018-12-03 08:13:00-05:00,CLVS,neutral
256025.0,"Clovis Oncology Shares Up 32% Premarket, Likely Trading Higher In Sympathy With 60% Upside Move In Tesaro Following $6B Deal For Glaxo To Buy Tesaro",2018-12-03 08:12:00-05:00,CLVS,positive
256026.0,Clovis Oncology Reports Second US Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035,2018-11-20 08:08:00-05:00,CLVS,positive
256027.0,75 Biggest Movers From Yesterday,2018-11-07 04:00:00-05:00,CLVS,neutral
256028.0,60 Stocks Moving In Tuesday's Mid-Day Session,2018-11-06 12:36:00-05:00,CLVS,neutral
256029.0,Armistice Capital Earlier Showed a 9.8% Stake in Clovis Oncology in a 13D Filing,2018-11-06 08:33:00-05:00,CLVS,neutral
256030.0,76 Biggest Movers From Yesterday,2018-11-02 06:12:00-04:00,CLVS,neutral
256031.0,"Stocks Which Set New 52-Week Low Yesterday, October 31st",2018-11-01 10:37:00-04:00,CLVS,negative
256032.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,CLVS,negative
256033.0,82 Biggest Movers From Yesterday,2018-11-01 04:38:00-04:00,CLVS,neutral
256034.0,66 Stocks Moving In Wednesday's Mid-Day Session,2018-10-31 12:50:00-04:00,CLVS,neutral
256035.0,8 Biggest Price Target Changes For Wednesday,2018-10-31 10:02:00-04:00,CLVS,neutral
256036.0,38 Stocks Moving In Wednesday's Pre-Market Session,2018-10-31 08:20:00-04:00,CLVS,neutral
256037.0,"The Daily Biotech Pulse: KemPharm, FDA Nod For Merck, Clovis Q3 Miss, 3 Stocks To Debut",2018-10-31 08:20:00-04:00,CLVS,negative
256038.0,"JP Morgan Downgrades Clovis Oncology to Neutral, Lowers Price Target to $16",2018-10-31 06:23:00-04:00,CLVS,positive
256039.0,Clovis Oncology shares are down 23.2% after the company missed Q3 EPS and sales estimates.,2018-10-30 17:15:00-04:00,CLVS,neutral
256040.0,Clovis Oncology Sees Q4 Sales Unchanged Or Slightly Higher Than Q3'18 Sales,2018-10-30 16:37:00-04:00,CLVS,neutral
256041.0,"Clovis Oncology Q3 EPS $(1.71) Misses $(1.64) Estimate, Sales $22.757M Miss $30.01M Estimate",2018-10-30 16:37:00-04:00,CLVS,negative
256042.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,CLVS,negative
256043.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,CLVS,neutral
256044.0,Clovis Oncology 8-K Shows Senior Vice President And Chief Commercial Officer Cowrin Dale Hooks Has Left Company,2018-10-29 17:14:00-04:00,CLVS,neutral
256045.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,CLVS,neutral
256046.0,Clovis Oncology 13G From Camber Capital Management Shows Raised Stake In Co. From 1M Shares To 3.5M Shares,2018-10-25 10:46:00-04:00,CLVS,positive
256047.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,CLVS,negative
256048.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,CLVS,negative
256049.0,"The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering",2018-10-24 07:48:00-04:00,CLVS,positive
256050.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,CLVS,negative
256051.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,CLVS,positive
256052.0,58 Biggest Movers From Yesterday,2018-10-23 05:09:00-04:00,CLVS,neutral
256053.0,45 Stocks Moving In Monday's Mid-Day Session,2018-10-22 12:39:00-04:00,CLVS,neutral
256054.0,58 Biggest Movers From Friday,2018-10-22 05:11:00-04:00,CLVS,neutral
256055.0,"The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs",2018-10-21 17:15:00-04:00,CLVS,neutral
256056.0,"'$CLVS -4%. Why? Rubraca prostate cancer data released today at #ESMO18 are fine, perhaps even better than expected, but ovarian competition is a big overhang to overcome.' -STAT News' Adam Feuerstein Tweets",2018-10-19 09:59:00-04:00,CLVS,negative
256057.0,Clovis Oncology shares are trading higher after the company's Rubraca study showed positive results.,2018-10-19 07:57:00-04:00,CLVS,positive
256058.0,Clovis Oncology Presents Initial Results from the Ongoing RubracaÂ® (rucaparib) TRITON Program in Metastatic Castration Resistant Prostate Cancer at ESMO 2018,2018-10-19 06:06:00-04:00,CLVS,negative
256059.0,"Stocks Which Set New 52-Week Low Yesterday, October 11th",2018-10-12 11:30:00-04:00,CLVS,negative
256060.0,"The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program",2018-10-12 07:34:00-04:00,CLVS,negative
256061.0,"Stocks Which Set New 52-Week Low Yesterday, October 10th",2018-10-11 09:11:00-04:00,CLVS,negative
256062.0,"The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares",2018-10-11 07:39:00-04:00,CLVS,positive
256063.0,"Stocks Which Set New 52-Week Low Yesterday, October 9th",2018-10-10 11:01:00-04:00,CLVS,negative
256064.0,45 Biggest Movers From Yesterday,2018-10-03 05:40:00-04:00,CLVS,neutral
256065.0,Mid-Afternoon Market Update: Stitch Fix Falls After Q4 Results; Pyxus International Shares Climb,2018-10-02 14:31:00-04:00,CLVS,positive
256066.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-10-02 13:51:00-04:00,CLVS,neutral
256067.0,Clovis Oncology Receives Breakthrough Therapy Designation From FDA For Its Rubraca (rucaparib) For Treatment Of BRCA1/2-Mutated Metastatic Castration Resistant Prostate Cancer,2018-10-02 08:05:00-04:00,CLVS,negative
256068.0,"The Daily Biotech Pulse: FDA Nods For Adamis, Eli Lilly, Pfizer; Spero, Obseva Report Positive Trial Results",2018-09-28 08:10:00-04:00,CLVS,positive
256069.0,"Stocks Which Set New 52-Week Low Yesterday, September 25th",2018-09-26 12:44:00-04:00,CLVS,negative
256070.0,"Leerink Swann Initiates Coverage On Clovis Oncology with Market Perform Rating, Announces $30 Price Target",2018-09-25 08:51:00-04:00,CLVS,neutral
256071.0,"Clovis Oncology CEO And Former CFO To Pay More Than $20M In Penalties, SEC Says Co. Misled Investors About Its Cancer Drug",2018-09-18 13:45:00-04:00,CLVS,negative
256072.0,"Stocks Which Set New 52-Week Low Yesterday, September 13th",2018-09-14 09:30:00-04:00,CLVS,negative
256073.0,"Stocks Which Set New 52-Week Low Yesterday, September 12th",2018-09-13 10:19:00-04:00,CLVS,negative
256074.0,"The Daily Biotech Pulse: Progenics Posts Mixed Trial Results, Antitrust Nod For Galapagos-MorphoSys Collaboration, New CEO For Biopharmx",2018-09-13 08:42:00-04:00,CLVS,neutral
256075.0,"Stocks Which Set New 52-Week Low Yesterday, September 11th",2018-09-12 15:29:00-04:00,CLVS,negative
256076.0,"Stocks Which Set New 52-Week Low Yesterday, August 8th",2018-08-09 11:10:00-04:00,CLVS,negative
256077.0,"The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings",2018-08-09 08:39:00-04:00,CLVS,positive
256078.0,"Stocks Which Set New 52-Week Low Yesterday, August 7th",2018-08-08 11:06:00-04:00,CLVS,negative
256079.0,"Stocks Which Set New 52-Week Low Yesterday, August 6th",2018-08-07 11:28:00-04:00,CLVS,negative
256080.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,CLVS,negative
256081.0,"Stocks Which Set New 52-Week Lows Friday, August 3rd",2018-08-06 13:20:00-04:00,CLVS,negative
256082.0,66 Biggest Movers From Friday,2018-08-06 05:36:00-04:00,CLVS,neutral
256083.0,56 Stocks Moving In Friday's Mid-Day Session,2018-08-03 12:27:00-04:00,CLVS,neutral
256084.0,"Stocks Which Set New 52-Week Low Yesterday, August 2nd",2018-08-03 11:22:00-04:00,CLVS,negative
256085.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,CLVS,neutral
256086.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,CLVS,positive
256087.0,"Clovis Oncology Q2 Adj. EPS $(1.55) Beats $(1.88) Estimate, Sales $23.8M Beat $22.44M Estimate",2018-08-01 17:04:00-04:00,CLVS,neutral
256088.0,Clovis Oncology Option Alert: Oct 19 $55 Calls at the Bid: 1612 @ $3.0 vs 344 OI; Earnings 8/1 After Close Ref=$45.73,2018-08-01 13:58:00-04:00,CLVS,positive
256089.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,CLVS,negative
256090.0,Clovis Oncology Option Alert: Sep 21 $60 Calls at the Ask: 500 @ $0.551 vs 144 OI; Earnings 8/1 After Close Ref=$43.36,2018-07-30 13:24:00-04:00,CLVS,positive
256091.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,CLVS,neutral
256092.0,"Clovis Oncology Receives EMA Validation for its Application for a New Indication for Rubraca, Says Timing Of Validation By EMA May Allow For CHMP Opinion On Maintenance Treatment By Year-End 2018",2018-07-05 08:01:00-04:00,CLVS,positive
256093.0,Clovis Oncology Option Alert: Jul 20 $50 Calls at the Ask: 1075 @ $2.25 vs 5441 OI; Earnings 8/1 After Close [est] Ref=$48.11,2018-06-22 14:20:00-04:00,CLVS,positive
256094.0,Clovis Oncology Submits an Application to the EMA to Expand Use of Rubraca,2018-06-04 06:05:00-04:00,CLVS,positive
256095.0,"Clovis Oncology, Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers",2018-06-03 20:56:00-04:00,CLVS,neutral
256096.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,CLVS,negative
256097.0,"Jim Cramer Advises His Viewers On Groupon, Adobe And More",2018-05-30 07:36:00-04:00,CLVS,neutral
256098.0,Clovis Oncology Announces European Commission Authorization of Rubraca for Women with Recurrent Ovarian Cancer,2018-05-29 08:01:00-04:00,CLVS,negative
256099.0,"Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway",2018-05-09 07:48:00-04:00,CLVS,neutral
256100.0,"Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure",2018-05-08 07:55:00-04:00,CLVS,neutral
256101.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,CLVS,neutral
256102.0,"Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings",2018-05-01 07:51:00-04:00,CLVS,neutral
256103.0,"Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings",2018-04-26 08:07:00-04:00,CLVS,neutral
256104.0,38 Biggest Movers From Yesterday,2018-04-17 04:46:00-04:00,CLVS,neutral
256105.0,Clovis Oncology Prices ~1.84M Share Offering @$54.41/Share,2018-04-17 04:02:00-04:00,CLVS,positive
256106.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-16 12:19:00-04:00,CLVS,neutral
256107.0,23 Stocks Moving In Monday's Pre-Market Session,2018-04-16 08:10:00-04:00,CLVS,neutral
256108.0,"In An 8-K Filing, Clovis Oncology Reported SEC Receipt Of 'Wells Notices' On April 9th",2018-04-10 09:37:00-04:00,CLVS,positive
256109.0,Clovis Announces FDA Approval For Rucaparib,2018-04-06 13:43:00-04:00,CLVS,positive
256110.0,REMINDER: Clovis Has FDA PDUFA Date For Rucaparib sNDA Today,2018-04-06 06:58:00-04:00,CLVS,neutral
256111.0,Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates,2018-04-03 08:14:00-04:00,CLVS,neutral
256112.0,"The Week Ahead: Switch's Lockup Expires, Spotify Debuts, And More",2018-04-02 15:35:00-04:00,CLVS,neutral
256113.0,"The Week Ahead In Biotech: PDUFA Dates, Clinical Trials And Conferences",2018-03-30 09:46:00-04:00,CLVS,neutral
256114.0,"For Now, Traders Endorse Biotech Rally",2018-03-28 11:43:00-04:00,CLVS,positive
256115.0,CHMP Grants Positive Opinion for Clovis Oncology's Rubraca Tablets,2018-03-23 09:00:00-04:00,CLVS,positive
256116.0,Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe,2018-03-23 09:00:00-04:00,CLVS,negative
256117.0,"Clovis Oncology Reports Initiation Of Early Access Program For Rucaparib As Treatment, Maintenance Therapy In Recurrent Ovarian Cancer In Europe",2018-03-23 08:56:00-04:00,CLVS,negative
256118.0,Clovis Oncology Reports CHMP Recommended Granting Of Conditional Marketing Authorization For Rubraca As Monotherapy Treatment Of Adult Patients With Cancer,2018-03-23 08:56:00-04:00,CLVS,negative
256119.0,Clovis Oncology Reports Notice Of Allowance For Rucaparib High-Dosage Strength Tablet Patent,2018-03-08 08:08:00-05:00,CLVS,positive
256120.0,Mid-Afternoon Market Update: Crude Oil Down 1.5%; Mallinckrodt Shares Climb After Strong Q4 Results,2018-02-27 14:30:00-05:00,CLVS,positive
256121.0,Mid-Day Market Update: U.S. Stocks Turn Lower; Dillard's Shares Gain On Earnings Beat,2018-02-27 12:00:00-05:00,CLVS,positive
256122.0,"Stifel Nicolaus Maintains Buy on Clovis Oncology, Lowers Price Target to $110.00",2018-02-27 09:58:00-05:00,CLVS,negative
256123.0,"Clovis Oncology Reports Q4 Adj. EPS $(1.27) vs $(1.30) Est., Sales $17.04M vs $20.1M Est.",2018-02-26 16:41:00-05:00,CLVS,neutral
256124.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-25 15:50:00-05:00,CLVS,neutral
256125.0,56 Biggest Movers From Yesterday,2018-02-23 05:17:00-05:00,CLVS,neutral
256126.0,45 Stocks Moving In Thursday's Mid-Day Session,2018-02-22 12:26:00-05:00,CLVS,neutral
256127.0,"Benzinga's Top Upgrades, Downgrades For February 22, 2018",2018-02-22 09:57:00-05:00,CLVS,positive
256128.0,"The Market In 5 Minutes: Jobless Claims Fall, 10-Year Treasury Yields, Twitter Makes Some Changes",2018-02-22 09:04:00-05:00,CLVS,positive
256129.0,Evercore ISI Group Upgrades Clovis Oncology to Outperform,2018-02-22 08:59:00-05:00,CLVS,neutral
256130.0,30 Stocks Moving In Thursday's Pre-Market Session,2018-02-22 07:54:00-05:00,CLVS,neutral
256131.0,RBC Capital Upgrades Clovis Oncology to Outperform,2018-02-22 06:33:00-05:00,CLVS,neutral
256132.0,Clovis Oncology Reports CHMP Has Communicated A Positive Trend Vote For Rucaparib MAA Under Review,2018-02-21 17:15:00-05:00,CLVS,positive
256133.0,"Clovis Shares Up 2.55%, Traders Attributing Strength To Chatroom Rumor Of M&A Interest",2018-02-20 10:07:00-05:00,CLVS,positive
256134.0,Clovis Oncology Reports Rucaparib MAA As Treatment For Ovarian Cancer Referred By CHMP To Scientific Advisory Group On Oncology For Review Expected In Feb. '18,2017-12-19 08:16:00-05:00,CLVS,negative
256135.0,Clovis Shars Pop To High Of $60.44/Share Up 1.2% On Day,2017-12-08 10:30:00-05:00,CLVS,neutral
256136.0,Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application,2017-12-05 16:05:00-05:00,CLVS,neutral
256137.0,"Stifel 2017 Healthcare Conference Concludes Today, Presenters Include: Eleven Biotherapeutics, Clovis, Puma Biotechnology, Synlogic, KalVista Pharmaceuticals, Dicerna Pharmaceuticals, GTx, and Acorda Therapeutics",2017-11-15 08:59:00-05:00,CLVS,neutral
256138.0,Credit Suisse Adjusts Its Top Picks List In A Record-Breaking Market,2017-11-08 17:10:00-05:00,CLVS,positive
256139.0,"Clovis Oncology Reports Q3 Adj. EPS $(1.24) vs $(1.22) Est., Sales $16.806M vs $21.12M Est.",2017-11-01 17:51:00-04:00,CLVS,neutral
256140.0,"Benzinga's Top Upgrades, Downgrades For October 23, 2017",2017-10-23 09:19:00-04:00,CLVS,positive
256141.0,"Barclays Initiates Coverage On Clovis Oncology with Overweight Rating, Announces $105.00 Price Target",2017-10-23 07:39:00-04:00,CLVS,negative
256142.0,"5 Stocks To Watch For October 10, 2017",2017-10-10 05:02:00-04:00,CLVS,neutral
256143.0,16 Stocks Moving In Monday's After-Hours Session,2017-10-09 18:30:00-04:00,CLVS,neutral
256144.0,Clovis Oncology Submits sNDA For Rucaparib,2017-10-09 16:05:00-04:00,CLVS,neutral
256145.0,"Clovis Shares Up 6.5% Wed. Following 4.7% Decline Over Tues.; Not Seeing Any Formal News To Justify Price Action But Stock Has Been Mentioned By The Rumor Mill At Least Twice Over 2017, Most Recently On Sept. 18",2017-09-27 13:26:00-04:00,CLVS,positive
256146.0,"Wall Street's M&A Chatter From September 18: Walgreens-Rite Aid, Northrup Grumman-Orbital ATK, Itron-Silver Spring Networks",2017-09-19 09:13:00-04:00,CLVS,neutral
256147.0,Clovis Oncology Higher Off Unconfirmed Takeover Chatter,2017-09-18 11:52:00-04:00,CLVS,negative
256148.0,"UPDATE: Clovis Spokesperson Says Co. 'remains focused on bringing Rubraca (rucaparib) to women with ovarian cancer and, eventually, to patients with other solid tumors that may be addressed by PARP inhibitors'",2017-09-18 10:41:00-04:00,CLVS,negative
256149.0,Clovis Oncology Spokesperson Declines Comment Following Chatroom Chatter Of Takeover Interest,2017-09-18 10:41:00-04:00,CLVS,positive
256150.0,Clovis Oncology Shares Now Up 6% Following Chatroom Chatter,2017-09-18 10:17:00-04:00,CLVS,positive
256151.0,Clovis Shares Spike ~$2 As Traders Circulate Takeover Chatter Via Chatroom,2017-09-18 10:10:00-04:00,CLVS,positive
256152.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,CLVS,neutral
256153.0,RBC Initiates Coverage on 6 Pharma Stocks After Hours,2017-09-14 16:47:00-04:00,CLVS,neutral
256154.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-09-13 08:04:00-04:00,CLVS,neutral
256155.0,"A Peek Into The Markets: U.S. Stock Futures Down Ahead Of Producer Price, Treasury Budget Data",2017-09-13 07:18:00-04:00,CLVS,positive
256156.0,"Clovis Oncology's Rucaparib ARIEL3 Study Met Primary, Secondary Endpoints",2017-09-13 06:04:00-04:00,CLVS,neutral
256157.0,"European Society for Medical Oncology(ESMO) 2017 Congress Begins Today, Day 1 Of 5",2017-09-08 09:15:00-04:00,CLVS,neutral
256158.0,25 Stocks Moving In Friday's Pre-Market Session,2017-09-08 08:05:00-04:00,CLVS,neutral
256159.0,Clovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017,2017-09-07 18:09:00-04:00,CLVS,positive
256160.0,"Evercore ISI Group Initiates Coverage On Clovis Oncology with In-Line Rating, Announces $73.00 Price Target",2017-08-17 07:19:00-04:00,CLVS,neutral
256161.0,"13F From Omega Shows Small, New Stakes In Bluebird Bio and Clovis Oncology",2017-08-14 10:30:00-04:00,CLVS,neutral
256162.0,A Biotech Binary Event Playbook: How To Play Clovis And Tesaro Ahead Of Label Decision,2017-08-08 14:36:00-04:00,CLVS,positive
256163.0,"Clovis Oncology Reports Q2 EPS $(3.88) vs $(2.13) Est., Sales $14.62M vs $13.31M Est.",2017-08-02 17:56:00-04:00,CLVS,neutral
256164.0,15 Biggest Mid-Day Losers For Monday,2017-07-31 12:52:00-04:00,CLVS,negative
256165.0,"Hearing JP Morgan Is Reiterating Their Overweight Rating; Says Clovis Takeover Is Not Off The Table Following Earlier News Of Partnership With Bristol-Myers, Explains That This Is A 'No-Strings'Attached' Clinical Collaboration",2017-07-31 10:18:00-04:00,CLVS,neutral
256166.0,22 Stocks Moving In Monday's Pre-Market Session,2017-07-31 08:39:00-04:00,CLVS,neutral
256167.0,Bristol-Myers and Clovis Oncology to Collaborate on Opdivo and Rubraca In Phase 2 and Phase 3 Trials,2017-07-31 07:00:00-04:00,CLVS,neutral
256168.0,Clovis Shares Now Up 3.38% At $96.03/Share,2017-07-07 11:30:00-04:00,CLVS,positive
256169.0,"Clovis Oncology Shares Spiking Higher, Gabelli & Co. Initiated On Company Earlier This Morning With A Buy And $125 Price Target",2017-07-07 10:58:00-04:00,CLVS,positive
256170.0,What To Expect From Clovis Oncology Following Rubraca Approval,2017-06-23 13:14:00-04:00,CLVS,positive
256171.0,12 Biggest Mid-Day Losers For Friday,2017-06-23 13:06:00-04:00,CLVS,negative
256172.0,"Benzinga's Top Upgrades, Downgrades For June 23, 2017",2017-06-23 09:23:00-04:00,CLVS,positive
256174.0,Oppenheimer Initiates Coverage On Clovis Oncology with Market Perform Rating,2017-06-23 07:30:00-04:00,CLVS,neutral
256177.0,Clovis Oncology Prices Upsized ~3.409M Share Offering @$88.00/Share,2017-06-21 04:09:00-04:00,CLVS,positive
256179.0,Clovis Addresses Some Of The Company's Biggest Controversies,2017-06-20 14:35:00-04:00,CLVS,neutral
256180.0,10 Biggest Mid-Day Gainers For Tuesday,2017-06-20 12:40:00-04:00,CLVS,neutral
256181.0,5 Biggest Price Target Changes For Tuesday,2017-06-20 09:51:00-04:00,CLVS,neutral
256182.0,"Benzinga's Top Upgrades, Downgrades For June 20, 2017",2017-06-20 09:27:00-04:00,CLVS,positive
256183.0,"Adam Feuerstein Tweets: I wrote about $CLVS potential takeout in The Readout this a.m. Subscribe, it's free, delivered to your inbox! statnews.com/signup/readout",2017-06-20 08:21:00-04:00,CLVS,positive
256184.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-06-20 08:09:00-04:00,CLVS,neutral
256185.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Fed Speakers,2017-06-20 07:19:00-04:00,CLVS,neutral
256186.0,Janney Capital Upgrades Clovis Oncology to Buy,2017-06-20 07:03:00-04:00,CLVS,neutral
256187.0,"7 Stocks To Watch For June 20, 2017",2017-06-20 05:25:00-04:00,CLVS,neutral
256188.0,Clovis Announces $250M Offering Common Stock,2017-06-19 16:01:00-04:00,CLVS,neutral
256189.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Clovis Oncology Shares Spike Higher,2017-06-19 14:47:00-04:00,CLVS,negative
256190.0,15 Biggest Mid-Day Gainers For Monday,2017-06-19 12:24:00-04:00,CLVS,neutral
256191.0,Mid-Day Market Update: Dow Gains 100 Points; Performant Financial Shares Tumble,2017-06-19 12:10:00-04:00,CLVS,positive
256192.0,Tesaro Comes Roaring Back From Much Lower Open,2017-06-19 11:48:00-04:00,CLVS,negative
256193.0,Mid-Morning Market Update: Markets Open Higher; EQT To Buy Rice Energy For $6.7B,2017-06-19 10:11:00-04:00,CLVS,positive
256194.0,"Benzinga's Top Upgrades, Downgrades For June 19, 2017",2017-06-19 09:31:00-04:00,CLVS,positive
256195.0,15 Stocks Moving In Monday's Pre-Market Session,2017-06-19 08:37:00-04:00,CLVS,neutral
256196.0,"Clovis Oncology's 45% Pre-Market Surge, Explained",2017-06-19 08:21:00-04:00,CLVS,neutral
256197.0,Chardan Capital Upgrades Clovis Oncology to Neutral,2017-06-19 08:08:00-04:00,CLVS,neutral
256198.0,Clovis Oncology Announces $142M Class Action Settlemet -8K,2017-06-19 06:13:00-04:00,CLVS,neutral
256199.0,Clovis Oncology Announces Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIEL3 Maintenance Treatment Trial; Plans to Submit sNDA,2017-06-19 04:10:00-04:00,CLVS,negative
256200.0,"Benzinga's Top Upgrades, Downgrades For June 13, 2017",2017-06-13 09:55:00-04:00,CLVS,positive
256201.0,"Leerink Swann Initiates Coverage On Clovis Oncology with Outperform Rating, Announces $85.00 Price Target",2017-06-13 06:09:00-04:00,CLVS,neutral
256202.0,"Companies Holding Shareholder Meetings Today Include: Aerie Pharma, Agile Therapeutics, bluebird bio, Bojangles, Comcast, Clovis Oncology, Etsy, Egalet, Dave And Busters, Ingersoll-Rand, Priceline, Lululemon, Rent-A-Center, Splunk, & Zoe's Kitchen",2017-06-08 09:41:00-04:00,CLVS,neutral
256203.0,"Adam Feuerstein Tweets '$TSRO ""for sale"" news  good reminder: Plenty 'o PARP data coming.  

$AZN OlympiAD breast at #ASCO17 (plenary)

$CLVS ARIEL-3 end of June'",2017-05-31 16:33:00-04:00,CLVS,positive
256204.0,"Tesaro, Clovis Shares Spike Higher Amid Report Tesaro is Exploring Sale, Has Asked for Initial Bids in Recent Weeks",2017-05-31 15:53:00-04:00,CLVS,positive
256205.0,"Benzinga's Top Upgrades, Downgrades For May 17, 2017",2017-05-17 09:25:00-04:00,CLVS,positive
256206.0,The Market In 5 Minutes,2017-05-17 09:00:00-04:00,CLVS,neutral
256207.0,20 Stocks Moving In Wednesday's Pre-Market Session,2017-05-17 08:07:00-04:00,CLVS,neutral
256208.0,JP Morgan Upgrades Clovis Oncology to Overweight,2017-05-17 06:28:00-04:00,CLVS,neutral
256209.0,Adam Feuerstein Tweets: Biotech Stock Mailbag: Why $CLVS is Trading Lower on Rubraca Study Update â> thestreet.com/story/14119676â¦ The PARP wars! $TSRO $AZN,2017-05-04 13:32:00-04:00,CLVS,negative
256210.0,"Clovis Oncology Reports Q1 EPS $(1.33) vs $(1.48) Est., Sales $7.045M May Not Compare $4.89M Est.",2017-05-03 17:40:00-04:00,CLVS,neutral
256211.0,Benzinga's Option Alert Recap From May 2,2017-05-02 16:55:00-04:00,CLVS,positive
256212.0,Option Alert: Clovis May 65.0 Calls: 1100 @  ASK  $1.60: 1584 traded vs 3367 OI:  Earnings tmrrw After Close  $57.63 Ref,2017-05-02 11:43:00-04:00,CLVS,positive
256213.0,Drug Trials Heating Up In The Breast and Ovarian Cancer Treatment Space,2017-04-27 12:55:00-04:00,CLVS,negative
256214.0,Myriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx Test to Identify Patients with Germline BRCA Mutations for Rubraca,2017-04-27 08:22:00-04:00,CLVS,positive
256215.0,"Tesaro Gets Approval For Zejula, Expect U.S. Launch Late April",2017-03-28 10:26:00-04:00,CLVS,positive
256216.0,"Tesaro Announces Expanded Development Program For Cancer Drug Niraparib, Stock Spikes Higher",2017-03-27 16:32:00-04:00,CLVS,negative
256217.0,Clovis Shares Selling Off On TESARO Approval Of niraparib,2017-03-27 15:39:00-04:00,CLVS,positive
256218.0,Clovis Spikes to High of $70.30,2017-03-27 15:24:00-04:00,CLVS,neutral
256219.0,Leerink Presents: Your 2017 Biopharma Catalyst Tracker,2017-03-20 09:17:00-04:00,CLVS,neutral
256220.0,Lynparza Vs. Niraparib,2017-03-15 08:32:00-04:00,CLVS,neutral
256221.0,Clovis Shares Reiterated As A Sell Following 10% Rally,2017-03-15 08:08:00-04:00,CLVS,positive
256222.0,Clovis Spikes to High of $65.78 on Volume Following Lynparza Results,2017-03-14 14:34:00-04:00,CLVS,neutral
256223.0,"Adam Feuerstein Tweets: $AZN Takes PARP Inhibitor Fight to Rival $TSRO with Strong Ovarian Cancer Study Results â> thestreet.com/story/14043007â¦ $CLVS, too.",2017-03-14 14:30:00-04:00,CLVS,negative
256224.0,"Adam Feuerstein Tweet $AZN Lynparza SOLO-2 ovarian cancer maintenance therapy data in 10 minutes. Watch $TSRO $CLVS for reaction, as well. Battle of the PARPs.",2017-03-14 14:21:00-04:00,CLVS,negative
256225.0,Wall Street's M&A Chatter From March 10-12,2017-03-13 07:01:00-04:00,CLVS,neutral
256226.0,Clovis Announces Presentation of New Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer at 2017 SGO Annual Meeting on Women's Cancer,2017-03-12 19:43:00-04:00,CLVS,negative
256227.0,"Clovis Says, In Their Recent 10-K, They Believe Macalinao Demand Letter To Investigate Alleged Misconduct Relating To rociletinib Is Unfounded And Fails To Establish An Entitlement To Any Of The Requested Documents",2017-02-24 10:23:00-05:00,CLVS,negative
256228.0,Clovis Oncology Reports Q4 Adj. EPS $(1.83) vs. $(1.65) Est.,2017-02-22 16:08:00-05:00,CLVS,neutral
256229.0,venBio Says It's Committed TO Delivering Much-Needed Change At Immunomedics In Shareholder Letter,2017-02-22 08:32:00-05:00,CLVS,positive
256230.0,Benzinga's Option Alert Recap From February 17,2017-02-17 17:12:00-05:00,CLVS,positive
256231.0,Option Alert: Clovis Feb $65 Call; 2983 @Bid @$0.35,2017-02-17 11:28:00-05:00,CLVS,positive
256232.0,"venBio Comments on Immunomedics Partnership Announcement, Says Co. Blatantly Spurning Will Of Stockholders",2017-02-10 16:16:00-05:00,CLVS,neutral
256233.0,State Street Reports 5.55% Passive Stake in Clovis Oncology in 13G,2017-02-09 07:18:00-05:00,CLVS,positive
256234.0,Clovis Oncology Sells off to Low of $61.10 on Volume,2017-02-06 13:38:00-05:00,CLVS,negative
256235.0,18 Biggest Mid-Day Losers For Friday,2017-02-03 12:44:00-05:00,CLVS,negative
256236.0,"Benzinga's Top Upgrades, Downgrades For February 3, 2017",2017-02-03 09:30:00-05:00,CLVS,positive
256237.0,25 Stocks Moving In Friday's Pre-Market Session,2017-02-03 08:12:00-05:00,CLVS,neutral
256238.0,"Chardan Capital Downgrades Clovis Oncology To Sell, Announces $36 Price Target",2017-02-03 07:06:00-05:00,CLVS,neutral
256239.0,"Clovis Oncology, Strata Oncology Partner to Accelerate Enrollment in Rucaparib Prostate Cancer Development Program",2017-02-01 08:30:00-05:00,CLVS,negative
256240.0,"Benzinga's Top Upgrades, Downgrades For January 27, 2017",2017-01-27 09:24:00-05:00,CLVS,positive
256241.0,Bank of America Initiates Coverage On Clovis Oncology At Buy,2017-01-27 08:00:00-05:00,CLVS,neutral
256242.0,"Benzinga's Top Upgrades, Downgrades For January 26, 2017",2017-01-26 09:22:00-05:00,CLVS,positive
256243.0,PiperJaffray Upgrades Clovis Oncology To Overweight,2017-01-26 08:30:00-05:00,CLVS,negative
256244.0,Which Pharma Players Dominate The Lung Cancer Space?,2017-01-25 14:40:00-05:00,CLVS,negative
256245.0,Here's What To Expect Following Trump's Drug Pricing 'Robbery' Comments,2017-01-17 11:33:00-05:00,CLVS,neutral
256246.0,Clovis Oncology Shares Up ~6% Friday Following Earlier New Overweight Rating from Morgan Stanley,2017-01-13 12:18:00-05:00,CLVS,negative
256247.0,"Clovis Shares Continue Recent Run Thurs., Up ~10%; Stock Up 22+% YTD, Up Nearly 90% Since Beginning of Nov.; Earlier 13G Filing from Integrated Core Strategies Showed New 5.1% Stake",2017-01-12 14:06:00-05:00,CLVS,positive
256248.0,Clovis Oncology Announces Prices Upsized 5M Share Offering @$41.00/Share,2017-01-04 04:37:00-05:00,CLVS,positive
256249.0,Hearing Clovis Oncology Offering Upsized and Expected to Price Around $41,2017-01-03 16:11:00-05:00,CLVS,neutral
256250.0,A Peek Into The Markets: U.S. Stock Futures Surge On First Trading Day Of 2017,2017-01-03 07:24:00-05:00,CLVS,neutral
256251.0,Clovis Oncology Announces $175M Offering,2017-01-03 06:47:00-05:00,CLVS,neutral
256252.0,Expect Availability Of Biogen's Newly Approved Spinraza In Just One Week,2016-12-27 14:32:00-05:00,CLVS,positive
256253.0,6 Best Biotech Stocks Of 2016,2016-12-23 11:25:00-05:00,CLVS,positive
256254.0,4 Stocks With Technical Momentum,2016-12-21 14:22:00-05:00,CLVS,neutral
256255.0,Breaking Down The Crowded Novel Ovarian Cancer Treatment Space,2016-12-21 09:19:00-05:00,CLVS,negative
256256.0,Clovis' Rubraca Vs. TESARO's Niraparib,2016-12-20 09:45:00-05:00,CLVS,neutral
256257.0,"Benzinga's Top Upgrades, Downgrades For December 20, 2016",2016-12-20 09:16:00-05:00,CLVS,positive
256258.0,"Chardan Capital Upgrades Clovis Oncology to Neutral, Announces $36.00 Target",2016-12-20 07:32:00-05:00,CLVS,neutral
256259.0,"Credit Suisse Says Clovis Oncology's Rubraca Accelerated Approval Comes With Best-Case Scenario Label, Increases Price Target From $41 To $50, Continues To See Clovis As Potential Takeout Target",2016-12-19 16:09:00-05:00,CLVS,positive
256260.0,Mid-Afternoon Market Update: Dow Gains Over 50 Points; Globalstar Shares Surge Following FCC News,2016-12-19 14:27:00-05:00,CLVS,positive
256261.0,Unexpected FDA Approval May Spark Extended Clovis Short Squeeze,2016-12-19 14:24:00-05:00,CLVS,positive
256262.0,"Clovis Oncology Opens, Spikes To $46.97, Now at $45",2016-12-19 13:20:00-05:00,CLVS,neutral
256263.0,Adam Feuerstein Tweets '$CLVS Rubraca approval has little bearing on $TSRO given different ovarian cancer pat pops. Rubraca more competes w/ $AZN Lynparza.',2016-12-19 13:08:00-05:00,CLVS,negative
256264.0,Clovis Oncology To Resume At 1:20pm ET,2016-12-19 13:03:00-05:00,CLVS,neutral
256265.0,PR Confirms Clovis Oncology Receives FDA Accelerated Approval of RUBRACA,2016-12-19 13:00:00-05:00,CLVS,positive
256266.0,FDA Approves Clovis Oncology's Ovarian Cancer Treatment,2016-12-19 11:53:00-05:00,CLVS,negative
256267.0,Code on Clovis Shares Switched from Circuit Breaker to News Pending,2016-12-19 11:18:00-05:00,CLVS,positive
256268.0,Clovis Shares to Resume Trade at 11:15:59 a.m. EST,2016-12-19 11:12:00-05:00,CLVS,positive
256269.0,TESARO Shares Spike ~$3 Lower Following News Out on Clovis' Rubraca,2016-12-19 11:11:00-05:00,CLVS,neutral
256270.0,Adam Feuerstein Tweets: $CLVS - FDA approves rucaparib for ovarian cancer. Brand name: Rubraca,2016-12-19 11:11:00-05:00,CLVS,negative
256271.0,Clovis Oncology Shares Spiking To $42 Level,2016-12-19 11:10:00-05:00,CLVS,positive
256272.0,"10 Stocks That Rallied Four Days, Then Sold Off Yesterday",2016-12-08 05:15:00-05:00,CLVS,neutral
256273.0,Clovis Oncology Up 4.6% On Yesterday's Publication Of rucaparib Data In The Lancet Oncology,2016-11-29 13:17:00-05:00,CLVS,neutral
256274.0,Vetr Crowd Doesn't Like Outlook For Clovis Oncology,2016-11-23 15:44:00-05:00,CLVS,negative
256275.0,Can You Guess This Chart?,2016-11-23 07:36:00-05:00,CLVS,neutral
256276.0,Clovis Spikes to High of $35.41 on Volume,2016-11-14 12:05:00-05:00,CLVS,neutral
256277.0,Clovis Oncology Reports Q3 EPS $(1.70) vs. Est. $(1.95),2016-11-03 17:41:00-04:00,CLVS,neutral
256278.0,Benzinga's Top Initiations,2016-10-25 09:32:00-04:00,CLVS,positive
256279.0,"The Market In 5 Minutes: UA, GM, P&G Earnings On The Street's Mind",2016-10-25 09:19:00-04:00,CLVS,neutral
256280.0,Chardan Recommends Selling Clovis Oncology,2016-10-25 07:47:00-04:00,CLVS,positive
256281.0,"Chardan Capital Initiates Coverage On Clovis Oncology, Inc. - Common Stock at Sell, Announces $15.00",2016-10-25 05:32:00-04:00,CLVS,neutral
256282.0,Watch These 7 Huge Call Purchases In Tuesday Trade,2016-10-18 01:00:00-04:00,CLVS,positive
256283.0,Option Alert: CLVS Oct16 30.0 Calls: 2400 @  Above Ask!  $2.60: 2560 traded vs 4906 OI:  Earnings 11/3  $31.96 Ref,2016-10-17 13:56:00-04:00,CLVS,positive
256284.0,"5 Stocks Which Rallied Four Days, Then Sold Off On Friday",2016-10-17 07:02:00-04:00,CLVS,neutral
256285.0,12 Stocks Which Rallied For Three Days,2016-10-14 08:57:00-04:00,CLVS,neutral
256286.0,15 Stocks That Rallied For Three Days On No News,2016-10-13 07:05:00-04:00,CLVS,negative
256287.0,Mid-Afternoon Market Update: Crude Oil Down 1.3%; Ruby Tuesday Shares Fall Following Q1 Results,2016-10-07 14:56:00-04:00,CLVS,negative
256288.0,18 Biggest Mid-Day Losers For Friday,2016-10-07 13:16:00-04:00,CLVS,negative
256289.0,Mid-Day Market Update: Dow Drops Over 100 Points; Gap Shares Rise Following September Sales Numbers,2016-10-07 12:13:00-04:00,CLVS,positive
256290.0,"Hearing SunTrust Analyst Issues Defense on Clovis, Highlighting 'Nothing Significantly New in Data'",2016-10-07 11:00:00-04:00,CLVS,positive
256291.0,Adam Feuerstein @adamfeuerstein Tweet: $CLVS falls on fears ovarian cancer drug inferior to competition thestreet.com/story/13845913â¦ Worry not ruca approval but comp. to $AZN Lynparza,2016-10-07 10:34:00-04:00,CLVS,negative
256292.0,Mid-Morning Market Update: Markets Open Lower; Silicon Motion Raises Q3 Forecast,2016-10-07 10:11:00-04:00,CLVS,negative
256293.0,Clovis Oncology Tumbles 20% On Rucaparib Data,2016-10-07 09:56:00-04:00,CLVS,neutral
256294.0,"Incyte Trading Higher, Up 3.4% Pre-market At $98/Share On Poor Clovis Data",2016-10-07 09:03:00-04:00,CLVS,negative
256295.0,"UPDATE: 9 Patients In Clovis Study Had AEs That Led To Death, 8 From Disease Progression and 1 From Sepsis, Which Investigator Assessed Was Unrelated To Treatment",2016-10-07 08:55:00-04:00,CLVS,negative
256297.0,European Society For Medical Oncology Conference Commences Today (Oct.7 Thru Oct. 11),2016-10-07 08:09:00-04:00,CLVS,neutral
256298.0,BZ NOTE: Clovis Oncology Shares Up 16+% Over Last Couple Weeks Since Takeover Chatter in Name Was First Heard,2016-10-05 10:17:00-04:00,CLVS,positive
256299.0,Hearing Takeover Chatter In Clovis Oncology,2016-10-05 10:09:00-04:00,CLVS,neutral
256300.0,"UPDATE: Clovis Says Lonza Will Be Non-Exclusive Manufacturer of Rucaparib API Until Dec. 31, 2025",2016-10-04 16:40:00-04:00,CLVS,neutral
256301.0,"8-K from Clovis Shows Co. Entered Long-Term Manufacture, Supply of Active Pharma Ingredient for Rucaparib",2016-10-04 16:39:00-04:00,CLVS,positive
256302.0,"Abstracts Expected Wednesday From Companies Presenting At The European Society For Medical Oncology Conf. Beginning Oct. 7th, Including From Karyopharm Therapeutics, Kite Pharma And Clovis Oncology",2016-10-04 08:35:00-04:00,CLVS,neutral
256303.0,Chasing Takeover Rumors Can Be Hazardous To Your Portfolio,2016-09-21 12:34:00-04:00,CLVS,neutral
256304.0,"Clovis Oncology Up 0.5% At $35.12, Janney Lowering Clovis On Chance That Clovis Will Need To Market rucaparib itself; But Raising PT From $30 To $36 For Potential M&A",2016-09-21 11:21:00-04:00,CLVS,neutral
256305.0,Hearing Clovis Oncology Downgraded To Neutral At Janney,2016-09-21 11:16:00-04:00,CLVS,neutral
256306.0,Benzinga's Volume Movers,2016-09-21 10:48:00-04:00,CLVS,neutral
256307.0,7 Biggest Price Target Changes For Wednesday,2016-09-21 10:15:00-04:00,CLVS,neutral
256308.0,More Pharma Deals In The Pipeline?,2016-09-21 09:56:00-04:00,CLVS,neutral
256309.0,Benzinga's Top Upgrades,2016-09-21 09:05:00-04:00,CLVS,positive
256310.0,"The Market In 5 Minutes: We're Waiting For You, Mrs. Yellen",2016-09-21 08:59:00-04:00,CLVS,neutral
256311.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-09-21 08:31:00-04:00,CLVS,neutral
256312.0,Clovis Upgraded At Credit Suisse Following Acquisition Rumor,2016-09-21 07:38:00-04:00,CLVS,positive
256313.0,"Credit Suisse Upgrades Clovis Oncology to Outperform, Raises PT to $41.00",2016-09-21 04:27:00-04:00,CLVS,positive
256314.0,"After-Hours Gainers Sept. 20, 2016: CLVS Up 10.3%, ADMS 6.1%, SPSC 5.6%, ADBE 5%, FDX 2.7%, KBH 2.2%, MSFT 1%, SRPT 1%",2016-09-20 17:59:00-04:00,CLVS,neutral
256315.0,"Some Traders Attributing After-Hours Upside in Clovis to Janney Capital Analyst Comment During Bloomberg Interview There Are 'Many Suitors' for Co, Including Lilly, Roche, Merck",2016-09-20 17:03:00-04:00,CLVS,neutral
256316.0,Clovis Oncology Shares Up Another 4% in Post-Market Action; Shares Closed Up 12.7% During Tuesday's Intraday Session,2016-09-20 16:52:00-04:00,CLVS,positive
256317.0,"Clovis Spokesperson Responds to Rumor Of Potential Acquisition By Eli Lilly, Tells Benzinga Co. Policy Is to Not Comment On Rumors",2016-09-20 15:28:00-04:00,CLVS,neutral
256318.0,Technical Alert: Rumor Mill Helps Clovis Oncology Near December Highs,2016-09-20 15:18:00-04:00,CLVS,positive
256319.0,Clovis Oncology Shares Now Up 10.3%; Off Session High of $34.92,2016-09-20 15:06:00-04:00,CLVS,positive
256320.0,Traders Attributing Spike Higher in Clovis Oncology to Unconfirmed Chatter of Lilly Interest,2016-09-20 14:58:00-04:00,CLVS,positive
256321.0,Clovis Shares Spiking Higher,2016-09-20 14:53:00-04:00,CLVS,positive
256322.0,"18 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-20 08:43:00-04:00,CLVS,neutral
256323.0,Mid-Afternoon Market Update: NASDAQ Turns Lower; Isle of Capri Casinos Shares Surge Following Merger News,2016-09-19 15:24:00-04:00,CLVS,neutral
256324.0,25 Stocks Which Rallied Three Days,2016-09-16 08:04:00-04:00,CLVS,neutral
256325.0,20 Stocks Which Rallied Three Days,2016-09-15 11:05:00-04:00,CLVS,neutral
256326.0,Technical Alert: Clovis Oncology Nears $30 For The First Time Since January,2016-09-08 14:22:00-04:00,CLVS,positive
256327.0,15 Biggest Mid-Day Gainers For Thursday,2016-09-08 12:59:00-04:00,CLVS,neutral
256328.0,Benzinga's Volume Movers,2016-09-08 10:37:00-04:00,CLVS,neutral
256329.0,Option Alert: CLVS Sep16 25.0 Calls: 699 @  ASK  $2.80: 2658 traded vs 5119 OI: $26.93 Ref,2016-09-08 10:28:00-04:00,CLVS,positive
256330.0,FDA Has Notified Clovis That FDA Is Not Currently Planning To Hold Advisory Committee Meeting To Discuss NDA For Rucaparib,2016-09-08 09:26:00-04:00,CLVS,neutral
256331.0,"15 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-02 14:03:00-04:00,CLVS,neutral
256332.0,18 Biggest Mid-Day Gainers For Wednesday,2016-08-24 12:56:00-04:00,CLVS,neutral
256333.0,Technical Alert: Clovis Oncology Finds Resistance,2016-08-24 12:08:00-04:00,CLVS,positive
256334.0,Benzinga's Volume Movers,2016-08-24 10:37:00-04:00,CLVS,neutral
256335.0,14 Stocks Moving In Wednesday's Pre-Market Session,2016-08-24 08:28:00-04:00,CLVS,neutral
256336.0,UPDATE: Clovis Oncology Shares Now Up 34.5% Following FDA Acceptance of NDA for Priority Review of Rucaparib,2016-08-23 14:42:00-04:00,CLVS,positive
256337.0,"Shares of Clovis Oncology Resume Trade, Continue Higher, Now Up 20%",2016-08-23 14:35:00-04:00,CLVS,positive
256338.0,Shares of Clovis Oncology to Resume Trade at 2:35:33 p.m. EDT,2016-08-23 14:33:00-04:00,CLVS,positive
256339.0,"UPDATE: Clovis Says PDUFA Date of Feb. 23, 2017 Set",2016-08-23 14:31:00-04:00,CLVS,neutral
256340.0,"Clovis Shares Halted on Circuit Breaker, Swings Into Positive Territory, Now Up 4.6%",2016-08-23 14:31:00-04:00,CLVS,positive
256341.0,Clovis Oncology Reports FDA Accepted NDA for Rucaparib for Priority Review,2016-08-23 14:30:00-04:00,CLVS,positive
256342.0,Mid-Morning Market Update: Markets Open Higher; Coach Profit Beats Views,2016-08-09 10:19:00-04:00,CLVS,positive
256343.0,Clovis Oncology Reports Q2 Adj. EPS (2.07) vs. Est. $(2.10),2016-08-08 16:48:00-04:00,CLVS,neutral
256344.0,Mid-Afternoon Market Update: Crude Oil Up 3.5%; Ceragon Shares Drop Following Q2 Results,2016-08-08 14:31:00-04:00,CLVS,negative
256345.0,The Market In 5 Minutes: Blowout Jobs Report Pushes Markets Higher,2016-08-05 08:55:00-04:00,CLVS,neutral
256346.0,SunTrust Robinson Humphrey Initiates Coverage on Clovis Oncology at Buy,2016-08-05 07:02:00-04:00,CLVS,neutral
256347.0,Clovis Higher In Sympathy With Tesaro,2016-06-29 14:10:00-04:00,CLVS,positive
256348.0,12 Biggest Mid-Day Gainers For Wednesday,2016-06-29 12:41:00-04:00,CLVS,neutral
256349.0,Benzinga's Volume Movers,2016-06-29 10:51:00-04:00,CLVS,neutral
256350.0,Clovis Oncology Up 19.38% At $14.70/Share In Sympathy To Tesaro,2016-06-29 10:13:00-04:00,CLVS,positive
256351.0,13 Stocks Moving In Wednesday's Pre-Market Session,2016-06-29 08:32:00-04:00,CLVS,neutral
256352.0,Watch These 7 Huge Put Purchases In Monday Trade,2016-06-27 02:51:00-04:00,CLVS,positive
256353.0,Option Alert: CLVS Jul16 10.0 Puts: 3290 @  ASK  $0.40: 4326 traded vs 1127 OI:  Earnings 8/4  $13.01 Ref,2016-06-24 15:23:00-04:00,CLVS,positive
256354.0,"7 Stocks Moving In Thursday's After-Hours Session: Oracle, Smith & Wesson And More",2016-06-16 16:50:00-04:00,CLVS,neutral
256355.0,8 Biggest Mid-Day Losers For Friday,2016-06-10 13:05:00-04:00,CLVS,negative
256356.0,S-3 from Clovis Oncology Shows Registration for $200M Mixed Securities Shelf Offering,2016-06-10 06:05:00-04:00,CLVS,positive
256357.0,Clovis Oncology Repost Phase 2 Rucaparib Data That Shows 38% Progression Recution,2016-06-06 08:33:00-04:00,CLVS,neutral
256358.0,Mid-Afternoon Market Update: Dow Rises Over 1%; Medivation Shares Gain On Reported Pushback Of Sanofi Takeover Effort,2016-04-13 15:47:00-04:00,CLVS,positive
256359.0,Mid-Day Market Update: Repros Therapeutics Jumps Following Encouraging Study Results; Clovis Oncology Shares Drop,2016-04-13 12:00:00-04:00,CLVS,positive
256360.0,"Clovis Investors Lose Roci Value Entirely, JPMorgan Sees Clovis Worth Just What Ruca Can Pay: $15/Share",2016-04-13 11:15:00-04:00,CLVS,positive
256361.0,Mid-Morning Market Update: Markets Open Higher; JPMorgan Beats Q1 Expectations,2016-04-13 10:07:00-04:00,CLVS,neutral
256362.0,Benzinga's Top Downgrades,2016-04-13 08:51:00-04:00,CLVS,positive
256363.0,10 Stocks Moving In Wednesday's Pre-Market Session,2016-04-13 08:18:00-04:00,CLVS,neutral
256364.0,UPDATE: JPMorgan Believes Best Way For Clovis To Unlock Value Would Be An Evaluation Of All Strategic Options For rucaparib To Extract Value,2016-04-13 07:57:00-04:00,CLVS,positive
256365.0,"JPMorgan Reports $15 Price Target On Clovis, Down From $110 PT In November 2015; Says Risk/Reward Call Was Admittedly Low-Probability Event, Believed There Was Enough Value To Support Call; Admits It Did Not WOrk",2016-04-13 07:56:00-04:00,CLVS,positive
256366.0,"JP Morgan Downgrades Clovis Oncology to Neutral, Lowers PT to $15.00",2016-04-13 05:12:00-04:00,CLVS,positive
256367.0,Clovis Oncology Plummets After Rociletinib Approval Rejected,2016-04-12 16:25:00-04:00,CLVS,negative
256368.0,Clovis Shares Down ~20%,2016-04-12 14:20:00-04:00,CLVS,positive
256369.0,"Clovis Shares Resume Trading, Opens Down Around $12.70",2016-04-12 14:20:00-04:00,CLVS,positive
256370.0,Clovis Shares To Resume Trading At 2:20pm EST,2016-04-12 14:02:00-04:00,CLVS,positive
256371.0,"Clovis Oncology Says They Are Disappointed With Today's Outcome, Believes In Strength Of rociletinib Data",2016-04-12 13:53:00-04:00,CLVS,neutral
256372.0,Clovis Stock Trading Halted Ahead Of FDA Meeting,2016-04-12 07:21:00-04:00,CLVS,neutral
256373.0,Clovis Oncology Shares Halted Ahead of FDA Panel Review of Rociletinib NDA for Treatment of Non-Small Cell Lung Cancer,2016-04-12 07:05:00-04:00,CLVS,negative
256374.0,Option Alert: CLVS Apr16 22.5 Calls: 500 @  Above Ask!  $0.76: 2410 traded vs 17k OI:  Earnings 5/4  $14.94 Ref,2016-04-11 14:05:00-04:00,CLVS,positive
256375.0,Stocks Hitting 52-Week Lows,2016-04-11 10:20:00-04:00,CLVS,negative
256376.0,Clovis Oncology Falls 8%: Here's What You Need To Know,2016-04-08 14:11:00-04:00,CLVS,neutral
256377.0,Hearing Stifel Cautious on Clovis,2016-04-08 10:55:00-04:00,CLVS,negative
256378.0,Adam F/Street.com: Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogether,2016-04-08 10:31:00-04:00,CLVS,negative
256379.0,Clovis Oncology Reports FDA Posted Briefing Docs for Panel Meeting to Review Rociletinib,2016-04-08 08:44:00-04:00,CLVS,neutral
256380.0,UPDATE: FDA Recommends Inclusion of Boxed Warning on Clovis' Drug,2016-04-08 08:00:00-04:00,CLVS,negative
256381.0,FDA Briefing Documents Out for Clovis' Lung Cancer Drug,2016-04-08 07:59:00-04:00,CLVS,negative
256382.0,Piper Jaffray Assumes Clovis Oncology at Neutral,2016-04-04 07:24:00-04:00,CLVS,neutral
256383.0,Clovis Oncology Spikes to High of $19.73 on Volume,2016-03-29 15:37:00-04:00,CLVS,neutral
256384.0,Option Alert: CLVS Apr16 35.0 Calls Sweep: 663 @  ASK  $0.86: 7851 traded vs 341 OI: $20.50 Ref,2016-03-02 15:21:00-05:00,CLVS,positive
256385.0,ption Alert: CLVS Apr16 22.5 Calls: 3000 @  Above Ask!  $4.00: 3245 traded vs 1015 OI: $20.47 Ref,2016-03-02 15:19:00-05:00,CLVS,positive
256386.0,Clovis Oncology Reports Q4 EPS $(2.23) Vs Est $(2.44),2016-02-25 16:53:00-05:00,CLVS,neutral
256387.0,"Clovis Oncology Issues Update On Rociletinib, Will Meet With FDA On April 12",2016-02-12 11:09:00-05:00,CLVS,neutral
256388.0,Clovis Oncology Reports NDA For Rociletinib At Upcoming FDA Oncologic Drugs Advisory Committee Meeting,2016-02-12 09:00:00-05:00,CLVS,neutral
256389.0,Goldman Sachs Reports 5.3% Passive Stake in Clovis Oncology,2016-02-10 09:40:00-05:00,CLVS,positive
256390.0,Clovis Oncology Initiates Immunotherapy Combination Trial,2016-01-27 08:01:00-05:00,CLVS,neutral
256391.0,"Credit Suisse Initiates Coverage on Clovis Oncology at Outperform, Announces $32.00 PT",2016-01-20 16:45:00-05:00,CLVS,positive
256392.0,10 Biotechs Short Sellers Are Betting Against,2015-12-29 08:22:00-05:00,CLVS,neutral
256393.0,6 Charts Costa Is Watching,2015-12-23 12:52:00-05:00,CLVS,neutral
256394.0,Benzinga's Top Initiations,2015-12-17 10:02:00-05:00,CLVS,positive
256395.0,"Janney Analyst Starts Clovis Oncology At Buy, Expects Regulatory Approvals Coming In 2016",2015-12-17 09:51:00-05:00,CLVS,neutral
256396.0,Janney Capital Initiates Coverage on Clovis Oncology at Buy,2015-12-17 05:56:00-05:00,CLVS,neutral
256397.0,Clovis Oncology Receives Notification of PDUFA Extension for Rociletinib,2015-12-15 16:16:00-05:00,CLVS,neutral
256398.0,Vetr Crowd No Longer Uber-Bearish On Puma Biotech,2015-12-11 13:16:00-05:00,CLVS,negative
256399.0,"Benzinga's M&A Chatter for Tuesday December 1, 2015",2015-12-01 19:29:00-05:00,CLVS,neutral
256400.0,Hearing Unconfirmed Market Chatter of Potential Amgen Interest in Clovis,2015-12-01 13:57:00-05:00,CLVS,positive
256401.0,Option Alert: CLVS Dec15 $30.0 Calls Sweep: 553 @  ASK  $2.90: 3118 traded vs 5293 OI: $31.31 Ref,2015-12-01 11:33:00-05:00,CLVS,positive
256402.0,Shares of Clovis Oncology Spike $2+; Hearing Kyle Bass Making Highly Bullish Comments on Name,2015-11-25 11:54:00-05:00,CLVS,positive
256403.0,Clovis Spikes Higher,2015-11-25 11:52:00-05:00,CLVS,neutral
256404.0,Clovis Shares Spiking,2015-11-25 11:52:00-05:00,CLVS,positive
256405.0,Clovis Oncology Continues Lower After Consolidation,2015-11-23 13:06:00-05:00,CLVS,negative
256406.0,Morning Market Losers,2015-11-17 09:56:00-05:00,CLVS,negative
256407.0,Benzinga's Top Downgrades,2015-11-17 09:26:00-05:00,CLVS,positive
256408.0,Wallachbeth Downgrades Clovis Oncology to Hold,2015-11-17 08:47:00-05:00,CLVS,neutral
256409.0,Benzinga's Top #PreMarket Losers,2015-11-17 08:18:00-05:00,CLVS,negative
256410.0,"Goldman Sachs Downgrades Clovis Oncology to Neutral, Lowers PT to $23.00",2015-11-17 07:21:00-05:00,CLVS,negative
256411.0,Mid-Afternoon Market Update: Dow Surges More Than 200 Points; Dillard's Shares Dip On Earnings Miss,2015-11-16 15:12:00-05:00,CLVS,positive
256412.0,Clovis Oncology Shares Unaffected Following Mid-Day Downgrade from Mizuho,2015-11-16 13:20:00-05:00,CLVS,positive
256413.0,Mid-Day Market Update: Starwood Drops Following Announcement of Acquisition Deal With Marriott; Sunoco Shares Gain,2015-11-16 12:16:00-05:00,CLVS,positive
256414.0,Clovis Oncology Plunges 70% In One Morning: What Happened?,2015-11-16 11:00:00-05:00,CLVS,neutral
256415.0,"What The FDA Gave Clovis Oncology In June 2013, It Has Taken Away",2015-11-16 10:45:00-05:00,CLVS,neutral
256416.0,Mid-Morning Market Update: Markets Edge Higher; Marriott To Acquire Starwood Hotels For $12.2B,2015-11-16 10:09:00-05:00,CLVS,neutral
256417.0,Morning Market Losers,2015-11-16 09:58:00-05:00,CLVS,negative
256418.0,Clovis Oncology Shares Resume Trading Down 60% Following Report of FDA Request for Additional Information on Lung Cancer Drug,2015-11-16 08:34:00-05:00,CLVS,negative
256419.0,Clovis Oncology to Resume Trading at 8:30 AM ET,2015-11-16 08:06:00-05:00,CLVS,neutral
256420.0,Clovis Oncology Announces Regulatory Update for Rociletinib NDA Filing,2015-11-16 08:05:00-05:00,CLVS,neutral
256421.0,Shares of Clovis Oncology Halted News Pending,2015-11-16 07:58:00-05:00,CLVS,positive
256422.0,AstraZeneca Halts 2 Lung Cancer Drug Combo Trials,2015-10-09 08:24:00-04:00,CLVS,negative
256423.0,Clovis Oncology Announces U.S. and E.U. Regulatory Milestones for Rociletinib in the Treatment of Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer,2015-09-29 16:01:00-04:00,CLVS,negative
256424.0,Biotechs Coming Off One Of The Busiest Weeks In Recent Memory,2015-09-14 13:44:00-04:00,CLVS,neutral
256425.0,Clovis Oncology Presentations for Tuesday September 8,2015-09-08 08:47:00-04:00,CLVS,neutral
256426.0,"Clovis Oncology Announces Data Presentations at 16th World Conference on Lung Cancer September 6-9, 2015",2015-09-04 06:03:00-04:00,CLVS,negative
256427.0,10 Biotech Stocks With Catalysts Coming Soon,2015-08-20 12:19:00-04:00,CLVS,neutral
256428.0,"Clovis Oncology Reports Entering Into of Clinical Trial Collaboration with Roche's Genentech for Evaluation of COL-1686, MPDL3280A Combo",2015-08-11 08:31:00-04:00,CLVS,neutral
256429.0,Clovis Oncology Could Pass $100 By Year-End: Here's Why,2015-08-08 16:51:00-04:00,CLVS,neutral
256430.0,Clovis Oncology Reports Q2 EPS of $(2.10) vs $(1.99) Est; Revenue of $0.00,2015-08-06 19:27:00-04:00,CLVS,neutral
256431.0,"Clovis Oncology Completes US, EU Regulatory Submissions for Rociletinib for Treatment of Advanced EGFR-Mutant T790M+ NSCLC",2015-08-03 06:03:00-04:00,CLVS,positive
256432.0,Benzinga's Top Upgrades,2015-07-20 09:14:00-04:00,CLVS,positive
256433.0,"Clovis Oncology, FibroGen Are Key Biotech Names For Goldman Sachs",2015-07-20 07:56:00-04:00,CLVS,neutral
256434.0,Goldman Sachs Upgrades Clovis Oncology to Conviction Buy,2015-07-20 04:57:00-04:00,CLVS,neutral
256435.0,Clovis Oncology Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock,2015-07-10 06:01:00-04:00,CLVS,positive
256436.0,Clovis Oncology Prices 3.525M Offering At $78/Share,2015-07-08 17:34:00-04:00,CLVS,neutral
256437.0,Clovis Oncology Announces $275M Secondary Offering,2015-07-07 16:05:00-04:00,CLVS,neutral
256438.0,Clovis Oncology Initiates Rolling NDA Submission to the FDA for Rociletinib in the Treatment of Advanced EGFR-Mutant Non-small Cell Lung Cancer,2015-07-01 16:06:00-04:00,CLVS,negative
256439.0,Clovis Oncology Appoints Dr. Lindsey Rolfe as Chief Medical Officer,2015-06-22 08:03:00-04:00,CLVS,neutral
256440.0,16 Biotech Stocks Moving Off The ASCO Conference,2015-06-01 15:51:00-04:00,CLVS,neutral
256441.0,"In CNBC Interview Clovis CEO Mahaffy Says Co. Will Apply For Lung Cancer Drug Approval In July, Expects Lung Drug To Come By End Of Year",2015-06-01 15:18:00-04:00,CLVS,negative
256442.0,Morning Market Losers,2015-06-01 10:25:00-04:00,CLVS,negative
256443.0,Benzinga's Top #PreMarket Losers,2015-06-01 08:16:00-04:00,CLVS,negative
256444.0,Clovis Oncology CO-1686 Phase 2 Study Results Demonstrate Consistent and Promising Clinical Activity and Disease Control in Very Advanced Patients with EGFR-Mutant NSCLC,2015-05-31 09:33:00-04:00,CLVS,positive
256445.0,Clovis Oncology's Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Highly Compelling Clinical Activity at ASCO,2015-05-30 20:35:00-04:00,CLVS,negative
256446.0,"Piper Jaffray Downgrades Clovis Oncology, Asks 'Point Of Maximal Optimism?'",2015-05-15 09:43:00-04:00,CLVS,neutral
256447.0,Stifel Talks 5 Biotech Stocks,2015-05-14 12:17:00-04:00,CLVS,neutral
256448.0,Clovis oncology Q1 EPS -$1.86 vs -$1.82 est,2015-05-06 15:57:00-04:00,CLVS,neutral
256449.0,"Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology",2015-05-06 08:46:00-04:00,CLVS,negative
256450.0,Benzinga's Volume Movers,2015-04-13 10:25:00-04:00,CLVS,neutral
256451.0,Morning Market Gainers,2015-04-13 09:41:00-04:00,CLVS,neutral
256452.0,Benzinga's Top Upgrades,2015-04-13 09:08:00-04:00,CLVS,positive
256453.0,Benzinga's Top #PreMarket Gainers,2015-04-13 08:12:00-04:00,CLVS,positive
256454.0,"Goldman Just Raised Its Clovis Oncology Target ~50%, Upgrades To Buy",2015-04-13 07:46:00-04:00,CLVS,neutral
256455.0,Goldman Sachs Upgrades Clovis Oncology To Buy,2015-04-13 07:45:00-04:00,CLVS,neutral
256456.0,"Goldman Sachs Upgrades Clovis Oncology to Buy, Raises PT to $117.00",2015-04-13 04:33:00-04:00,CLVS,neutral
256457.0,Benzinga's Volume Movers,2015-04-07 10:59:00-04:00,CLVS,neutral
256458.0,Morning Market Gainers,2015-04-07 09:39:00-04:00,CLVS,neutral
256459.0,Benzinga's Top #PreMarket Gainers,2015-04-07 08:14:00-04:00,CLVS,positive
256460.0,Clovis Oncology Given Breakthrough Therapy Designation for Rucaparib for Monotherapy Treatment of Advanced Ovarian Cancer in Patients with BRCA-mutated Tumors (Inclusive of both Germline and Somatic BRCA Mutations),2015-04-06 16:03:00-04:00,CLVS,negative
256461.0,18 Biotech Stocks These Wall Street Analysts Are Tracking,2015-03-11 12:04:00-04:00,CLVS,neutral
256462.0,Clovis Oncology Reports Q4 EPS of $(1.62),2015-02-25 16:20:00-05:00,CLVS,neutral
256463.0,"Earnings Scheduled For February 25, 2015",2015-02-25 04:07:00-05:00,CLVS,neutral
256464.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1,2015-01-12 08:55:00-05:00,CLVS,neutral
256465.0,Morning Market Losers,2014-11-19 09:53:00-05:00,CLVS,negative
256466.0,Clovis Oncology Shares Trade Almost 9% Lower Premarket Following Mixed Report on CO-1686 Phase 2 Data,2014-11-19 08:12:00-05:00,CLVS,positive
256467.0,Clovis Oncology Enters Into Oncology Clinical Trial Collaboration With GlaxoSmithKline,2014-11-17 17:00:00-05:00,CLVS,neutral
256468.0,UPDATE: Stifel Reiterates On Clovis Oncology Following 3Q14 LPS,2014-11-07 08:33:00-05:00,CLVS,neutral
256469.0,"Stifel Nicolaus Maintains Buy on Clovis Oncology, Inc., Raises PT to $75.00",2014-11-07 07:36:00-05:00,CLVS,neutral
256470.0,Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer ,2014-10-23 16:53:00-04:00,CLVS,negative
256471.0,Clovis Oncology Announces Encouraging Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer ,2014-09-28 09:58:00-04:00,CLVS,negative
256472.0,Clovis Oncology Spikes to High,2014-09-26 14:06:00-04:00,CLVS,neutral
256473.0,Morning Market Losers ,2014-09-03 09:50:00-04:00,CLVS,negative
256474.0,Biotech Enters Reporting Season With Large Caps Central To Sector Performance,2014-07-18 15:40:00-04:00,CLVS,neutral
256475.0,US Stock Futures Flat Ahead Of Manufacturing PMI,2014-06-23 07:41:00-04:00,CLVS,neutral
256476.0,Clovis Oncology ReportsFirst Patient Enrolled in TIGER2 Study ,2014-06-23 06:06:00-04:00,CLVS,neutral
256477.0,Market Wrap For June 5: Markets Positive Before Friday's Employment Report,2014-06-05 16:35:00-04:00,CLVS,positive
256478.0,UPDATE: Stifel Upgrades Clovis Oncology On Favorable Risk/Reward,2014-06-05 10:38:00-04:00,CLVS,positive
256479.0,"Stifel Nicolaus Upgrades Clovis Oncology, Inc. to Buy",2014-06-05 06:41:00-04:00,CLVS,neutral
256480.0,"Market Wrap For June 4: Markets Slightly Higher On Light Volume, Beige Book",2014-06-04 16:38:00-04:00,CLVS,neutral
256481.0,"Citi Downgrades Clovis, Rates It As High Risk",2014-06-04 08:32:00-04:00,CLVS,negative
256482.0,Market Wrap For June 3: Markets Run Out Of Steam,2014-06-03 16:44:00-04:00,CLVS,neutral
256483.0,"Mid-Day Market Movers For Tuesday, June 3, 2014",2014-06-03 14:10:00-04:00,CLVS,neutral
256484.0,Stocks Hitting 52-Week Lows,2014-06-03 10:18:00-04:00,CLVS,negative
256485.0,Morning Market Losers ,2014-06-03 09:48:00-04:00,CLVS,negative
256486.0,Benzinga's Top #PreMarket Losers,2014-06-03 08:18:00-04:00,CLVS,negative
256487.0,"Citigroup Downgrades Clovis Oncology, Inc. to Neutral",2014-06-03 07:27:00-04:00,CLVS,neutral
256488.0,"Market Wrap For June 2: Dow, S&P Continue Rising, Nasdaq Slightly Lower",2014-06-02 16:36:00-04:00,CLVS,negative
256489.0,"Mid-Afternoon Market Update; ISM Revised Twice, CONN Maintains Gains On Earnings Report",2014-06-02 15:56:00-04:00,CLVS,positive
256490.0,Mid-Day Market Update: MasTec Tumbles On Weak Forecast; Protective Life Shares Spike Higher,2014-06-02 12:51:00-04:00,CLVS,negative
256491.0,âMid-Morning Market Update: Markets Fall; Conn's Profit Beats Street View,2014-06-02 10:54:00-04:00,CLVS,positive
256492.0,Morning Market Losers ,2014-06-02 09:46:00-04:00,CLVS,negative
256493.0,Benzinga's Top #PreMarket Losers,2014-06-02 08:18:00-04:00,CLVS,negative
256494.0,Clovis Presents Encouraging Data from Phase 1/2a Study Evaluating Lucitanib in Advanced Solid Tumors at ASCO,2014-05-31 13:21:00-04:00,CLVS,positive
256495.0,Clovis Oncology Presents Positive Phase 1/2 Rucaparib Results at ASCO,2014-05-31 12:59:00-04:00,CLVS,positive
256496.0,Morning Market Movers ,2014-05-20 09:45:00-04:00,CLVS,neutral
256497.0,Benzinga's Top #PreMarket Gainers ,2014-05-20 08:20:00-04:00,CLVS,positive
256498.0,Clovis Oncology Reports Has Received Breakthrough Therapy Designation for CO-1686,2014-05-19 16:00:00-04:00,CLVS,neutral
256499.0,Market Wrap For May 15: Bears Return In Full-Force As Dow Suffers Triple-Digit Point Loss,2014-05-15 16:41:00-04:00,CLVS,negative
256500.0,Afternoon Market Movers,2014-05-15 15:53:00-04:00,CLVS,neutral
256501.0,Mid-Afternoon Market Update: Markets Remain Red Despite Slight Recovery; Zendesk IPO Goes Off Without A Hitch,2014-05-15 15:45:00-04:00,CLVS,neutral
256502.0,Mid-Day Market Update: Dow Drops Over 200 Points; Cisco Shares Jump On Upbeat Results,2014-05-15 12:41:00-04:00,CLVS,positive
256503.0,Benzinga's Volume Movers ,2014-05-15 10:39:00-04:00,CLVS,neutral
256504.0,Mid-Morning Market Update: Markets Tumble; Wal-Mart Posts Lower Profit,2014-05-15 10:18:00-04:00,CLVS,positive
256505.0,UPDATE: Clovis Oncology Shares Rise 15% Following Announcement of Presentation of Positive Data at ASCO,2014-05-15 09:41:00-04:00,CLVS,positive
256506.0,Morning Market Movers ,2014-05-15 09:36:00-04:00,CLVS,neutral
256507.0,Benzinga's Top #PreMarket Gainers,2014-05-15 08:09:00-04:00,CLVS,positive
256508.0,UPDATE: Clovis Oncology Shares Rise 8% After-Hours on Announcement of Presentation of Clinical Data as ASCO ,2014-05-14 17:57:00-04:00,CLVS,positive
256509.0,"Clovis Oncology, Inc. Reports Q1 EPS of $(0.91) vs $(0.85) Est; Revenue of $13.60M",2014-05-08 16:34:00-04:00,CLVS,neutral
256510.0,"Foundation Medicine, Clovis Oncology Expand Collaboration",2014-04-03 06:36:00-04:00,CLVS,positive
256511.0,Benzinga's Volume Movers,2014-03-27 10:34:00-04:00,CLVS,neutral
256512.0,Benzinga's Top #PreMarket Gainers,2014-03-27 08:20:00-04:00,CLVS,positive
256513.0,UPDATE: Clovis Oncology Shares Rise 12% Premarket on Positive Phase 1 Trial Results for NSCLC Treatment,2014-03-27 07:54:00-04:00,CLVS,positive
256514.0,"US Stock Futures Rise; GDP, Jobless Claims Data In Focus",2014-03-27 07:33:00-04:00,CLVS,neutral
256515.0,Clovis Oncology's CO-1686 Demonstrates Compelling Clinical Activity and Progression-free Survival in Updated Phase 1 Study Results in Patients with NSCLC ,2014-03-27 05:36:00-04:00,CLVS,positive
256516.0,Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast,2014-03-26 10:24:00-04:00,CLVS,neutral
256517.0,Benzinga's Top Initiations,2014-03-24 08:21:00-04:00,CLVS,positive
256518.0,"Goldman Sachs Initiates Coverage on Clovis Oncology, Inc. at Neutral, Announces $90.00 PT",2014-03-24 07:42:00-04:00,CLVS,neutral
256519.0,"Clovis Oncology, Inc. Reports Q4 EPS of $(0.92) vs $(0.78) Est",2014-02-27 16:24:00-05:00,CLVS,neutral
256520.0,Clovis Oncology Expands CO-1686 Development Program ,2014-02-27 16:22:00-05:00,CLVS,positive
256521.0,Clovis Oncology Says Earnings to be Released Toward End of February; Some Websites Show Company Reporting Today,2014-01-30 14:08:00-05:00,CLVS,neutral
256522.0,Mid-Day Market Update: SodaStream Drops After Weak Outlook; Beam Shares Spike Higher,2014-01-13 12:52:00-05:00,CLVS,negative
256523.0,Mid-Morning Market Update: Markets Open Lower; Lululemon Lowers Q4 Outlook,2014-01-13 10:39:00-05:00,CLVS,negative
256524.0,Benzinga's Top #PreMarket Gainers,2014-01-13 08:21:00-05:00,CLVS,positive
256525.0,"Clovis Oncology Announces 2014 Objectives, Financial Guidance ",2014-01-13 07:34:00-05:00,CLVS,neutral
256526.0,Clovis Shares Spike Higher After-Hours on CNBC Comments it is Next Intercept,2014-01-10 17:28:00-05:00,CLVS,positive
256527.0,US Stock Futures Rise Ahead Of Consumer Sentiment Data,2013-12-23 06:59:00-05:00,CLVS,neutral
256528.0,Clovis Oncology CO-1686 Clinical Data Accepted as Oral Presentation at 2014 ELCC,2013-12-23 06:07:00-05:00,CLVS,positive
256529.0,Clovis Oncology Announces 2M Share Offering  by Selling Stockholders ,2013-12-02 16:09:00-05:00,CLVS,positive
256530.0,"Benzinga's M&A Chatter for Tuesday November 19, 2013",2013-11-19 17:58:00-05:00,CLVS,neutral
256531.0,"Clovis Oncology Buys EOS SpA for Upfront Payment of $190M in Stock, $10M in Cash",2013-11-19 16:35:00-05:00,CLVS,neutral
256532.0,Why Clovis Oncology Was The Short Trade Of The Day,2013-11-19 15:28:00-05:00,CLVS,neutral
256533.0,UPDATE: H.C. Wainwright nitiates on Clovis Oncology On Prospects Of CO-1686,2013-11-15 08:18:00-05:00,CLVS,positive
256534.0,"HC Wainwright & Co. Initiates Coverage on Clovis Oncology, Inc. at Neutral, Announces $55.00 PT",2013-11-15 07:44:00-05:00,CLVS,neutral
256535.0,Mid-Morning Market Update: Markets Mixed; Merck Profit Beats Estimates,2013-10-28 10:35:00-04:00,CLVS,positive
256536.0,Clovis Oncology's CO-1686 Demonstrates Promising Clinical Activity and Safety in Phase I Study,2013-10-27 19:36:00-04:00,CLVS,positive
256537.0,QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations,2013-10-21 16:02:00-04:00,CLVS,neutral
256538.0,Mid-Day Market Update: Dow Falls Over 100 Points; Active Network Shares Jump,2013-09-30 13:12:00-04:00,CLVS,positive
256539.0,Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net Profit Declines 7%,2013-09-30 10:31:00-04:00,CLVS,positive
256540.0,"Shares of Clovis Oncology Down 4+% Following Mixed Ariad Data on AP26113, Data on AZD9291 from AstraZeneca",2013-09-30 09:30:00-04:00,CLVS,positive
256541.0,Mid-Day Market Update: US Stocks Turn Higher; MAKO Surgical Shares Surge On Acquisition News,2013-09-25 12:55:00-04:00,CLVS,positive
256542.0,Mid-Morning Market Update: Markets Slip; AutoZone Q4 Net Profit Rises 15%,2013-09-25 10:31:00-04:00,CLVS,positive
256543.0,Morning Market Losers ,2013-09-25 09:56:00-04:00,CLVS,negative
256544.0,"Benzinga's M&A Chatter for Tuesday September 24, 2013",2013-09-24 17:18:00-04:00,CLVS,neutral
256545.0,Bloomberg Reporting Clovis Oncology Said to Get No Interest from Buyers,2013-09-24 16:28:00-04:00,CLVS,positive
256546.0,Benzinga's Top Initiations,2013-09-20 07:48:00-04:00,CLVS,positive
256547.0,"Citigroup Initiates Coverage on Clovis Oncology, Inc. at Buy, Announces $109.00 PT",2013-09-20 07:44:00-04:00,CLVS,neutral
256548.0,"Benzinga's M&A Chatter for Tuesday September 17, 2013",2013-09-17 16:56:00-04:00,CLVS,neutral
256549.0,"Clovis Oncology Spokesperson Says Company was Not Source of Bloomberg Article, Not Commenting on the Rumor",2013-09-17 14:19:00-04:00,CLVS,neutral
256550.0,"Shares of Clovis Resume Trade, Now Up 17%",2013-09-17 13:52:00-04:00,CLVS,positive
256551.0,"Shares of Clovis Oncology Halted on Limit-Up, Limit-Down, Stock Halted Up 11%",2013-09-17 13:50:00-04:00,CLVS,positive
256552.0,Bloomberg Reporting Clovis Oncology Said to Weight Sale of $2B Biotech Firm,2013-09-17 13:47:00-04:00,CLVS,neutral
256553.0,"UPDATE: Stifel Initiates Coverage on Clovis Oncology, Awaiting More Attractive Entry Point",2013-09-06 10:05:00-04:00,CLVS,positive
256554.0,"Stifel Nicolaus Initiates Coverage on Clovis Oncology, Inc. at Hold",2013-09-06 08:25:00-04:00,CLVS,neutral
256555.0,These ETFs House The Next Biotech Takeover Targets,2013-08-26 07:44:00-04:00,CLVS,neutral
256556.0,"Clovis Oncology, Inc. Reports Q2 EPS of $(0.72) vs $(0.65) Est",2013-08-01 07:53:00-04:00,CLVS,neutral
256557.0,"Mizuho Securities Initiates Coverage on Clovis Oncology, Inc. at Buy, Announces $90.00 PT",2013-06-25 09:14:00-04:00,CLVS,positive
256558.0,UPDATE: Piper Jaffray Lowers PT on Clovis Oncology to Reflect Recent Financing,2013-06-18 11:23:00-04:00,CLVS,negative
256559.0,"Piper Jaffray Maintains Overweight on Clovis Oncology, Inc., Lowers PT to $87.00",2013-06-18 09:10:00-04:00,CLVS,negative
256560.0,Clovis Oncology Announces 2 New Board Members,2013-06-13 16:03:00-04:00,CLVS,neutral
256561.0,Clovis Oncology Announces Full Exercise of Underwriters' Over-Allotment Option,2013-06-13 16:03:00-04:00,CLVS,neutral
256562.0,Clovis Oncology Pricing 3.33M Share Offering at $72/Share,2013-06-12 05:58:00-04:00,CLVS,positive
256563.0,A Peek Into The Market Before The Trading Starts,2013-06-10 07:16:00-04:00,CLVS,neutral
256564.0,Clovis Oncology Announces $170M Offering of Common Stock ,2013-06-10 06:10:00-04:00,CLVS,neutral
256565.0,Benzinga's Top Pre-Market Gainers ,2013-06-07 08:12:00-04:00,CLVS,positive
256566.0,UPDATE: Piper Jaffray Upgrades Clovis Oncology to Overweight Following CO-1686 Data Presentation,2013-06-06 10:07:00-04:00,CLVS,negative
256567.0,Benzinga's Top Upgrades,2013-06-06 07:51:00-04:00,CLVS,positive
256568.0,"Piper Jaffray Upgrades Clovis Oncology, Inc. to Overweight, Raises PT to $100.00",2013-06-06 06:28:00-04:00,CLVS,negative
256569.0,This Stock Was Up More Than 100 Percent Monday,2013-06-04 08:28:00-04:00,CLVS,neutral
256570.0,"Market Wrap for Monday, June 3: Stocks Rise to Start Week ",2013-06-03 16:13:00-04:00,CLVS,neutral
256571.0,Mid-Afternoon Market Update: Markets Recovering; Pandora Falls in Anticipation of Apple's Streaming Radio,2013-06-03 15:41:00-04:00,CLVS,positive
256572.0,Afternoon Market Gainers,2013-06-03 13:26:00-04:00,CLVS,neutral
256573.0,"Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News",2013-06-03 12:27:00-04:00,CLVS,positive
256574.0,Benzinga's Volume Movers,2013-06-03 10:44:00-04:00,CLVS,neutral
256575.0,"BioMarin Shares Remain at Lows Despite Piper Jaffray Note Defending News of Clovis, Tesaro Data Updates at ASCO, Says BioMarin's BMN-673 'Looks Competitive;' Reiterates Overweight, $70 Target",2013-06-03 10:33:00-04:00,CLVS,negative
256576.0,Morning Market Movers,2013-06-03 09:50:00-04:00,CLVS,neutral
256577.0,Clovis Oncology's Rucaparib Shows Encouraging Results from Ongoing Phase I/II Study,2013-06-03 07:35:00-04:00,CLVS,positive
256578.0,"JP Morgan Maintains Overweight on Clovis Oncology, Inc., Raises PT to $45.00",2013-05-07 15:51:00-04:00,CLVS,neutral
256579.0,UPDATE: J.P. Morgan Raises PT on Clovis Oncology on Growing Optimism,2013-03-11 11:05:00-04:00,CLVS,positive
256580.0,"JP Morgan Maintains Overweight on Clovis Oncology, Inc., Raises PT to $33.00",2013-03-11 08:18:00-04:00,CLVS,neutral
256581.0,UPDATE: Piper Jaffray Initiates Clovis Oncology with Neutral Rating on Strong Valuation,2013-03-06 08:30:00-05:00,CLVS,positive
256582.0,"Piper Jaffray Initiates Coverage on Clovis Oncology, Inc. at Neutral, Announces $20.00 PT",2013-03-05 16:12:00-05:00,CLVS,neutral
256583.0,Mid-Afternoon Market Update: Markets Near Flat; J.C. Penney Falling Further,2012-11-12 16:04:00-05:00,CLVS,negative
256584.0,Mid-Day Market Update: Markets Slow Their Rally; JC Penney Spikes Lower,2012-11-12 12:49:00-05:00,CLVS,negative
256585.0,Mid-Morning Market Update: Markets Continue Cautious Rally; Jefferies Acquired by Leucadia ,2012-11-12 10:21:00-05:00,CLVS,negative
256586.0,Benzinga's Top Pre-Market Losers,2012-11-12 08:22:00-05:00,CLVS,negative
256587.0,Clovis Oncology Announces Negative Results from  Pancreatic Cancer Study ,2012-11-12 06:24:00-05:00,CLVS,negative
256588.0,Clovis Oncology Reports Q3 EPS $-0.71 vs $-0.67 Est,2012-11-05 16:19:00-05:00,CLVS,neutral
256589.0,Clovis Oncology and Array BioPharma Announce Agreement to Discover Novel Mutant KIT Inhibitor   ,2012-07-16 16:31:00-04:00,CLVS,positive
256590.0,Clovis Oncology Announces Pricing of 3.75M Share Offering at $20.00  ,2012-04-04 06:58:00-04:00,CLVS,positive
256591.0,Market Update,2012-03-23 11:30:00-04:00,CLVS,neutral
256592.0,Clovis Oncology Announces Proposed Public Offering of $75M Shares ,2012-03-23 06:46:00-04:00,CLVS,positive
256593.0,Clovis Oncology Announces FDA Acceptance of Investigational New Drug Application for Oral EGFR Mutant-Selective Inhibitor CO-1686  ,2012-01-19 16:32:00-05:00,CLVS,positive
256594.0,"End-of-Day Market Summary for January 18, 2012",2012-01-18 16:16:00-05:00,CLVS,neutral
256595.0,Afternoon Movers; Markets Moved Higher,2012-01-18 16:06:00-05:00,CLVS,neutral
256596.0,UPDATE: JP Morgan Initiates Clovis Oncology at Overweight,2012-01-03 12:12:00-05:00,CLVS,neutral
256597.0,JP Morgan Initiates Clovis Oncology at Overweight,2012-01-03 06:51:00-05:00,CLVS,neutral
256598.0,JP Morgan Initiates Clovis Oncology at Overweight,2012-01-03 06:51:00-05:00,CLVS,neutral
